



Clinical trial results:

A Multicenter, Randomized, Addition to Baseline Treatment, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) in Patients with Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Summary

| | |
|--------------------------|-------------------|
| EudraCT number | 2013-003752-21 |
| Trial protocol | GB DE IT PL HU ES |
| Global end of trial date | 23 December 2022 |

Results information

| | |
|--------------------------------|---|
| Result version number | v3 (current) |
| This version publication date | 29 January 2023 |
| First version publication date | 27 September 2020 |
| Version creation reason | <ul style="list-style-type: none">• Correction of full data setAnalysis stage correction |

Trial information

Trial identification

| | |
|-----------------------|---------|
| Sponsor protocol code | BN40898 |
|-----------------------|---------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT02028884 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | Hoffmann-La Roche |
| Sponsor organisation address | Grenzacherstrasse 124, Basel, Switzerland, CH-4070 |
| Public contact | F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com |
| Scientific contact | Medical Communications, Hoffmann-La Roche, 41 616878333, global.trial_information@roche.com |

Notes:

Paediatric regulatory details

| | |
|--|---------------------|
| Is trial part of an agreed paediatric investigation plan (PIP) | Yes |
| EMA paediatric investigation plan number(s) | EMA-001625-PIP01-14 |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 23 June 2021 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 23 December 2022 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The main objective of this study was to evaluate the efficacy of satralizumab, compared with placebo, in addition to baseline immunosuppressive treatment in participants with neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD).

Protection of trial subjects:

All study subjects were required to read and sign an Informed Consent Form.

Background therapy:

All patients received azathioprine or mycophenolate mofetil and/or corticosteroids as background therapy

Evidence for comparator: -

| | |
|---|------------------|
| Actual start date of recruitment | 20 February 2014 |
| Long term follow-up planned | Yes |
| Long term follow-up rationale | Safety |
| Long term follow-up duration | 1 Years |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-------------------|
| Country: Number of subjects enrolled | Poland: 23 |
| Country: Number of subjects enrolled | Japan: 22 |
| Country: Number of subjects enrolled | Taiwan: 13 |
| Country: Number of subjects enrolled | France: 1 |
| Country: Number of subjects enrolled | United States: 2 |
| Country: Number of subjects enrolled | Germany: 4 |
| Country: Number of subjects enrolled | Italy: 9 |
| Country: Number of subjects enrolled | Spain: 3 |
| Country: Number of subjects enrolled | Hungary: 2 |
| Country: Number of subjects enrolled | Ukraine: 3 |
| Country: Number of subjects enrolled | United Kingdom: 3 |
| Worldwide total number of subjects | 85 |
| EEA total number of subjects | 42 |

Notes:

| Subjects enrolled per age group | |
|---|----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 9 |
| Adults (18-64 years) | 72 |
| From 65 to 84 years | 4 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Participants took part in the double-blind (DB) period up to the primary clinical cut-off date (06 June 2018) and in the Open-label Extension Period until the final clinical cut-off date (23-Dec-2021). All ongoing patients have been offered to transition to the WN42349 study

Period 1

| | |
|------------------------------|-------------------------|
| Period 1 title | Double-blind Period |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator |

Arms

| | |
|------------------------------|---|
| Are arms mutually exclusive? | Yes |
| Arm title | Placebo + Baseline Treatment, then Satralizumab |

Arm description:

Participants received matching placebo, subcutaneous (SC) at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | Satralizumab |
| Investigational medicinal product code | |
| Other name | SA237 RG6168 RO5333787 |
| Pharmaceutical forms | Concentrate for solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Satralizumab was administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).

| | |
|--|--|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Placebo was administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).

| | |
|------------------|--|
| Arm title | Satralizumab + Baseline Treatment, then Satralizumab |
|------------------|--|

Arm description:

Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD. At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W

thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Placebo was administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).

| | |
|--|--|
| Investigational medicinal product name | Satralizumab |
| Investigational medicinal product code | |
| Other name | SA237 RG6168 RO5333787 |
| Pharmaceutical forms | Concentrate for solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Satralizumab was administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).

| | |
|------------------|--------------------------------|
| Arm title | SA237 - Enrolled in Open-Label |
|------------------|--------------------------------|

Arm description:

In the open-label extension period, the participant received an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter, in addition to baseline treatment

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | Satralizumab |
| Investigational medicinal product code | |
| Other name | SA237 RG6168 RO5333787 |
| Pharmaceutical forms | Concentrate for solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Satralizumab was administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).

| Number of subjects in period 1 | Placebo + Baseline Treatment, then Satralizumab | Satralizumab + Baseline Treatment, then Satralizumab | SA237 - Enrolled in Open-Label |
|---------------------------------------|---|--|--------------------------------|
| Started | 42 | 42 | 1 |
| Completed | 32 | 39 | 1 |
| Not completed | 10 | 3 | 0 |
| Consent withdrawn by subject | 2 | - | - |
| Adverse event, non-fatal | 5 | 3 | - |
| Eligibility Violation | 1 | - | - |
| Non-Compliance With Study Drug | 2 | - | - |

Period 2

| | |
|------------------------------|-----------------------------|
| Period 2 title | Open-label Extension Period |
| Is this the baseline period? | No |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|---|
| Are arms mutually exclusive? | Yes |
| Arm title | Placebo + Baseline Treatment, then Satralizumab |

Arm description:

Participants received matching placebo, subcutaneous (SC) at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Satralizumab |
| Investigational medicinal product code | |
| Other name | SA237 RG6168 RO5333787 |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Satralizumab was administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).

| | |
|------------------|--|
| Arm title | Satralizumab + Baseline Treatment, then Satralizumab |
|------------------|--|

Arm description:

Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD. At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Satralizumab |
| Investigational medicinal product code | |
| Other name | SA237 RG6168 RO5333787 |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Satralizumab was administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).

| | |
|------------------|--------------------------------|
| Arm title | SA237 - Enrolled in Open-Label |
|------------------|--------------------------------|

Arm description:

In the open-label extension period, the participant received an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter, in addition to baseline treatment

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Satralizumab |
| Investigational medicinal product code | |
| Other name | SA237 RG6168 RO5333787 |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Satralizumab was administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).

| Number of subjects in period 2 | Placebo + Baseline Treatment, then Satralizumab | Satralizumab + Baseline Treatment, then Satralizumab | SA237 - Enrolled in Open-Label |
|---------------------------------------|--|---|---------------------------------------|
| Started | 32 | 39 | 1 |
| Completed | 23 | 31 | 1 |
| Not completed | 9 | 8 | 0 |
| Consent withdrawn by subject | - | 6 | - |
| Adverse event, non-fatal | 3 | 1 | - |
| Switched to another treatment option | 3 | - | - |
| Refused Treatment/Did Not Cooperate | - | 1 | - |
| Lack of efficacy | 3 | - | - |

Baseline characteristics

Reporting groups

| | |
|-----------------------|---|
| Reporting group title | Placebo + Baseline Treatment, then Satralizumab |
|-----------------------|---|

Reporting group description:

Participants received matching placebo, subcutaneous (SC) at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|-----------------------|--|
| Reporting group title | Satralizumab + Baseline Treatment, then Satralizumab |
|-----------------------|--|

Reporting group description:

Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD. At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|-----------------------|--------------------------------|
| Reporting group title | SA237 - Enrolled in Open-Label |
|-----------------------|--------------------------------|

Reporting group description:

In the open-label extension period, the participant received an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter, in addition to baseline treatment

| Reporting group values | Placebo + Baseline Treatment, then Satralizumab | Satralizumab + Baseline Treatment, then Satralizumab | SA237 - Enrolled in Open-Label |
|--|---|--|--------------------------------|
| Number of subjects | 42 | 42 | 1 |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 3 | 5 | 1 |
| Adults (18-64 years) | 38 | 34 | 0 |
| From 65-84 years | 1 | 3 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Age Continuous | | | |
| Units: Years | | | |
| arithmetic mean | 43.4 | 40.2 | 16.0 |
| standard deviation | ± 12.0 | ± 16.3 | ± 0 |
| Sex: Female, Male | | | |
| Units: | | | |
| Male | 2 | 4 | 0 |
| Female | 40 | 38 | 1 |

| | | | |
|---|----|----|---|
| Race/Ethnicity, Customized Units: Subjects | | | |
| Not Hispanic or Latino | 40 | 42 | 1 |
| Not Stated | 2 | 0 | 0 |
| Race/Ethnicity, Customized Units: Subjects | | | |
| Asian | 18 | 18 | 0 |
| Black or African American | 2 | 0 | 0 |
| White | 21 | 24 | 0 |
| Other | 1 | 0 | 1 |

| | | | |
|---|-------|--|--|
| Reporting group values | Total | | |
| Number of subjects | 85 | | |
| Age categorical Units: Subjects | | | |
| In utero | 0 | | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | | |
| Newborns (0-27 days) | 0 | | |
| Infants and toddlers (28 days-23 months) | 0 | | |
| Children (2-11 years) | 0 | | |
| Adolescents (12-17 years) | 9 | | |
| Adults (18-64 years) | 72 | | |
| From 65-84 years | 4 | | |
| 85 years and over | 0 | | |
| Age Continuous Units: Years | | | |
| arithmetic mean | | | |
| standard deviation | - | | |
| Sex: Female, Male Units: | | | |
| Male | 6 | | |
| Female | 79 | | |
| Race/Ethnicity, Customized Units: Subjects | | | |
| Not Hispanic or Latino | 83 | | |
| Not Stated | 2 | | |
| Race/Ethnicity, Customized Units: Subjects | | | |
| Asian | 36 | | |
| Black or African American | 2 | | |
| White | 45 | | |
| Other | 2 | | |

Subject analysis sets

| | |
|----------------------------|------------------------------|
| Subject analysis set title | Placebo + Baseline Treatment |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received matching placebo, subcutaneous (SC) at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse or treated

relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|----------------------------|-----------------------------------|
| Subject analysis set title | Satralizumab + Baseline Treatment |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD. At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|----------------------------|-----------------------------------|
| Subject analysis set title | Satralizumab + Baseline Treatment |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD. At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|----------------------------|------------------------------|
| Subject analysis set title | Placebo + Baseline Treatment |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received matching placebo, subcutaneous (SC) at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|----------------------------|-----------------------------------|
| Subject analysis set title | Satralizumab + Baseline Treatment |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD. At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|----------------------------|------------------------------|
| Subject analysis set title | Placebo + Baseline Treatment |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received matching placebo, subcutaneous (SC) at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|----------------------------|-----------------------------------|
| Subject analysis set title | Satralizumab + Baseline Treatment |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter

throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD. At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|----------------------------|------------------------------|
| Subject analysis set title | Placebo + Baseline Treatment |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received matching placebo, subcutaneous (SC) at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|----------------------------|-----------------------------------|
| Subject analysis set title | Satralizumab + Baseline Treatment |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD. At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|----------------------------|-----------------------------------|
| Subject analysis set title | Satralizumab + Baseline Treatment |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD. At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| Reporting group values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | Satralizumab + Baseline Treatment |
|---|------------------------------|-----------------------------------|-----------------------------------|
| Number of subjects | 42 | 42 | 41 |
| Age categorical Units: Subjects | | | |
| In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over | | | |
| Age Continuous Units: Years | | | |
| arithmetic mean | 43.4 | 40.2 | ± |
| standard deviation | ± 12.00 | ± 16.3 | |

| | | | |
|----------------------------|----|----|--|
| Sex: Female, Male | | | |
| Units: | | | |
| Male | 2 | 4 | |
| Female | 40 | 38 | |
| Race/Ethnicity, Customized | | | |
| Units: Subjects | | | |
| Not Hispanic or Latino | 40 | 42 | |
| Not Stated | 2 | 0 | |
| Race/Ethnicity, Customized | | | |
| Units: Subjects | | | |
| Asian | 18 | 18 | |
| Black or African American | 2 | 0 | |
| White | 21 | 24 | |
| Other | 1 | 0 | |

| Reporting group values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | Placebo + Baseline Treatment |
|--|------------------------------|-----------------------------------|------------------------------|
| Number of subjects | 34 | 37 | 16 |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | | | |
| Preterm newborn infants (gestational age < 37 wks) | | | |
| Newborns (0-27 days) | | | |
| Infants and toddlers (28 days-23 months) | | | |
| Children (2-11 years) | | | |
| Adolescents (12-17 years) | | | |
| Adults (18-64 years) | | | |
| From 65-84 years | | | |
| 85 years and over | | | |
| Age Continuous | | | |
| Units: Years | | | |
| arithmetic mean | | | |
| standard deviation | ± | ± | ± |
| Sex: Female, Male | | | |
| Units: | | | |
| Male | | | |
| Female | | | |
| Race/Ethnicity, Customized | | | |
| Units: Subjects | | | |
| Not Hispanic or Latino | | | |
| Not Stated | | | |
| Race/Ethnicity, Customized | | | |
| Units: Subjects | | | |
| Asian | | | |
| Black or African American | | | |
| White | | | |
| Other | | | |

| Reporting group values | Satralizumab + Baseline Treatment | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment |
|------------------------|-----------------------------------|------------------------------|-----------------------------------|
| Number of subjects | 13 | 41 | 40 |

| | | | |
|--|---|---|---|
| Age categorical Units: Subjects | | | |
| In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over | | | |
| Age Continuous Units: Years arithmetic mean standard deviation | ± | ± | ± |
| Sex: Female, Male Units: | | | |
| Male Female | | | |
| Race/Ethnicity, Customized Units: Subjects | | | |
| Not Hispanic or Latino Not Stated | | | |
| Race/Ethnicity, Customized Units: Subjects | | | |
| Asian Black or African American White Other | | | |

| | | | |
|--|--------------------------------------|--|--|
| Reporting group values | Satralizumab + Baseline Treatment | | |
| Number of subjects | 75 | | |
| Age categorical Units: Subjects | | | |
| In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over | | | |
| Age Continuous Units: Years arithmetic mean standard deviation | ± | | |

| | | | |
|--|--|--|--|
| Sex: Female, Male Units: | | | |
| Male Female | | | |
| Race/Ethnicity, Customized Units: Subjects | | | |
| Not Hispanic or Latino Not Stated | | | |
| Race/Ethnicity, Customized Units: Subjects | | | |
| Asian Black or African American White Other | | | |

End points

End points reporting groups

| | |
|---|--|
| Reporting group title | Placebo + Baseline Treatment, then Satralizumab |
| Reporting group description: | |
| Participants received matching placebo, subcutaneous (SC) at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period. | |
| Reporting group title | Satralizumab + Baseline Treatment, then Satralizumab |
| Reporting group description: | |
| Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD. At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period. | |
| Reporting group title | SA237 - Enrolled in Open-Label |
| Reporting group description: | |
| In the open-label extension period, the participant received an SC injection of satralizumab at Weeks 0,2, and 4, and Q4W thereafter, in addition to baseline treatment | |
| Reporting group title | Placebo + Baseline Treatment, then Satralizumab |
| Reporting group description: | |
| Participants received matching placebo, subcutaneous (SC) at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period. | |
| Reporting group title | Satralizumab + Baseline Treatment, then Satralizumab |
| Reporting group description: | |
| Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD. At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period. | |
| Reporting group title | SA237 - Enrolled in Open-Label |
| Reporting group description: | |
| In the open-label extension period, the participant received an SC injection of satralizumab at Weeks 0,2, and 4, and Q4W thereafter, in addition to baseline treatment | |
| Subject analysis set title | Placebo + Baseline Treatment |
| Subject analysis set type | Per protocol |
| Subject analysis set description: | |
| Participants received matching placebo, subcutaneous (SC) at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period. | |

| | |
|----------------------------|-----------------------------------|
| Subject analysis set title | Satralizumab + Baseline Treatment |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD. At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|----------------------------|-----------------------------------|
| Subject analysis set title | Satralizumab + Baseline Treatment |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD. At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|----------------------------|------------------------------|
| Subject analysis set title | Placebo + Baseline Treatment |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received matching placebo, subcutaneous (SC) at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|----------------------------|-----------------------------------|
| Subject analysis set title | Satralizumab + Baseline Treatment |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD. At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|----------------------------|------------------------------|
| Subject analysis set title | Placebo + Baseline Treatment |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received matching placebo, subcutaneous (SC) at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|----------------------------|-----------------------------------|
| Subject analysis set title | Satralizumab + Baseline Treatment |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD. At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|----------------------------|------------------------------|
| Subject analysis set title | Placebo + Baseline Treatment |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received matching placebo, subcutaneous (SC) at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|----------------------------|-----------------------------------|
| Subject analysis set title | Satralizumab + Baseline Treatment |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD. At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

| | |
|----------------------------|-----------------------------------|
| Subject analysis set title | Satralizumab + Baseline Treatment |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD. At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

Primary: Time to First Protocol-Defined Relapse (TFR) in the Double-Blind Period

| | |
|-----------------|---|
| End point title | Time to First Protocol-Defined Relapse (TFR) in the Double-Blind Period |
|-----------------|---|

End point description:

TFR was defined as time from randomization to first occurrence of relapse in the DB period. Protocol-defined relapse was occurrence of new or worsening neurological symptoms attributable to neurological neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) as adjudicated by an independent clinical endpoint committee (CEC). Symptoms had to persist for >24 hours and not be attributable to confounding clinical factors (e.g., fever, infection, injury, change in mood, adverse reactions to medications). New or worsening neurological symptoms that occurred < 31 days following onset of a protocol-defined relapse were considered part of same relapse (i.e., if 2 relapses had onset days that were 30 days of one another, they were counted only as 1 relapse), and onset date used in analysis was the date of first relapse.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to Week 224

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|----------------------------------|------------------------------|-----------------------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: weeks | | | | |
| median (confidence interval 95%) | 120.6 (37.0 to 9999) | 0000 (0000 to 9999) | | |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | Stratified analysis |
| Statistical analysis description: Stratified by Baseline annualized relapse rate (ARR: 1, > 1) and geographic region (Asia, EU/Other). | |
| Comparison groups | Placebo + Baseline Treatment v Satralizumab + Baseline Treatment |
| Number of subjects included in analysis | 83 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.0184 |
| Method | Logrank |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.38 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.16 |
| upper limit | 0.88 |

Secondary: Change from Baseline at Week 24 in the Visual Analogue Scale (VAS) Score for Pain During the DB Period

| | |
|--|--|
| End point title | Change from Baseline at Week 24 in the Visual Analogue Scale (VAS) Score for Pain During the DB Period |
| End point description: The VAS is a subjective measure of pain consisting of a 100 mm line with two endpoints representing 0 = "no pain" and 100 = "pain as bad as it could be". Participants rated their pain by placing a mark on the line corresponding to their current level of pain. The distance along the line from the "no pain" marker was measured with a ruler giving a pain score out of 100. A higher score indicated more pain and lower scores reflected a better health state. A negative change from baseline indicates an improvement. ANCOVA was used for analysis to report the adjusted mean and standard error (SE). | |
| End point type | Secondary |
| End point timeframe: Baseline, Week 24 | |

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|----------------------------------|------------------------------|-----------------------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: score on scale | | | | |
| arithmetic mean (standard error) | | | | |

| | | | | |
|---------------------------------|-----------------------|-----------------------|--|--|
| Baseline | 34.619 (\pm 4.026) | 27.561 (\pm 4.399) | | |
| Change from Baseline at Week 24 | -3.505 (\pm 2.357) | 2.871 (\pm 2.391) | | |

Statistical analyses

| Statistical analysis title | Statistical analysis |
|---|--|
| Comparison groups | Placebo + Baseline Treatment v Satralizumab + Baseline Treatment |
| Number of subjects included in analysis | 83 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.0602 |
| Method | ANCOVA |
| Parameter estimate | Mean difference (final values) |
| Point estimate | 6.376 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.28 |
| upper limit | 13.033 |
| Variability estimate | Standard error of the mean |
| Dispersion value | 3.344 |

Secondary: Change from Baseline at Week 24 in the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Score During the DB Period

| | |
|--|--|
| End point title | Change from Baseline at Week 24 in the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Score During the DB Period |
| End point description: | |
| The FACIT Fatigue scale is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days. As each of the 13 items of the scale ranges from 0-4, the range of possible scores was computed using FACIT scoring algorithm as 0-52, where 0 is the worst possible score and 52 the best which indicated less fatigue. A positive change from baseline indicates an improvement. ANCOVA was used for analysis to report the adjusted mean and SE. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline, Week 24 | |

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|----------------------------------|------------------------------|-----------------------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: score on scale | | | | |
| arithmetic mean (standard error) | | | | |

| | | | | |
|---------------------------------|-----------------------|-----------------------|--|--|
| Baseline | 33.857 (\pm 1.746) | 34.732 (\pm 1.646) | | |
| Change from Baseline at Week 24 | 2.234 (\pm 0.943) | 0.145 (\pm 0.963) | | |

Statistical analyses

| Statistical analysis title | Statistical analysis |
|---|--|
| Comparison groups | Placebo + Baseline Treatment v Satralizumab + Baseline Treatment |
| Number of subjects included in analysis | 83 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.1224 |
| Method | ANCOVA |
| Parameter estimate | Mean difference (final values) |
| Point estimate | -2.089 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.752 |
| upper limit | 0.574 |
| Variability estimate | Standard error of the mean |
| Dispersion value | 1.338 |

Secondary: Relapse-Free Rate During the DB Period

| End point title | Relapse-Free Rate During the DB Period |
|---|--|
| End point description: | |
| Protocol-defined relapse was occurrence of new or worsening neurological symptoms attributable to neurological neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD). Symptoms had to persist for >24 hours and not be attributable to confounding clinical factors (e.g., fever, infection, injury, change in mood, adverse reactions to medications). New or worsening neurological symptoms that occurred < 31 days following onset of a protocol-defined relapse were considered part of same relapse (i.e., if 2 relapses had onsets within 30 days of one another, they were counted as 1), and onset date used in analysis was the date of first relapse. | |
| End point type | Secondary |
| End point timeframe: | |
| Up to Week 216 | |

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|-----------------------------------|------------------------------|-----------------------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 34 | 37 | | |
| Units: percentage of participants | | | | |
| number (not applicable) | | | | |
| Week 12 | 89.86 | 94.99 | | |

| | | | | |
|----------|-------|-------|--|--|
| Week 24 | 84.41 | 88.86 | | |
| Week 36 | 69.49 | 88.86 | | |
| Week 48 | 66.02 | 88.86 | | |
| Week 72 | 58.68 | 81.46 | | |
| Week 96 | 58.68 | 77.58 | | |
| Week 120 | 54.17 | 73.70 | | |
| Week 144 | 49.24 | 73.70 | | |
| Week 168 | 43.77 | 73.70 | | |
| Week 192 | 0000 | 73.70 | | |
| Week 216 | 0000 | 73.70 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Annualized Relapse Rate (ARR) During the DB Period

| | |
|--|--|
| End point title | Annualized Relapse Rate (ARR) During the DB Period |
| End point description: | |
| The ARR is calculated as the total number of participants with relapses experienced divided by the patient-years at risk. Protocol-defined relapse was occurrence of new or worsening neurological symptoms attributable to neurological NMO or NMOSD. Symptoms had to persist for >24 hours and not be attributable to confounding clinical factors (e.g., fever, infection, injury, change in mood, adverse reactions to medications). New or worsening neurological symptoms that occurred < 31 days following onset of a protocol-defined relapse were considered part of same relapse (2 relapses with onset days in 30 days of one another was counted as 1 relapse), onset date used in analysis was the date of first relapse. | |
| End point type | Secondary |
| End point timeframe: | |
| Up to Week 216 | |

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|---|------------------------------|-----------------------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: patients w relapse/patient-years at risk | | | | |
| number (confidence interval 95%) | 0.32 (0.19 to 0.51) | 0.11 (0.05 to 0.21) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Modified Rankin Scale (mRS) Scores at 24 Week Intervals During the DB Period

| | |
|-----------------|--|
| End point title | Change from Baseline in Modified Rankin Scale (mRS) Scores |
|-----------------|--|

End point description:

The mRS is a 7-point disability scale that assesses the degree of disability in participants with neurological impairment. Possible scores range from 0 (no symptoms at all) up to 6 (death). Higher scores reflect increased disability. A negative change from baseline indicates an improvement.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Week 216

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|--------------------------------------|------------------------------------|---|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: score on scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 1.55 (± 0.97) | 1.90 (± 1.14) | | |
| Change from Baseline at Week 24 | -0.03 (± 0.42) | -0.03 (± 0.50) | | |
| Change from Baseline at Week 48 | -0.18 (± 0.53) | -0.13 (± 0.45) | | |
| Change from Baseline at Week 72 | 0.07 (± 0.70) | 0.00 (± 0.52) | | |
| Change from Baseline at Week 96 | 0.13 (± 0.62) | -0.19 (± 0.51) | | |
| Change from Baseline at Week 120 | -0.10 (± 0.74) | -0.05 (± 0.51) | | |
| Change from Baseline at Week 144 | -0.11 (± 0.93) | -0.20 (± 0.41) | | |
| Change from Baseline at Week 168 | -0.67 (± 0.58) | -0.11 (± 0.33) | | |
| Change from Baseline at Week 192 | 0.00 (± 0.00) | -0.50 (± 0.71) | | |
| Change from Baseline at Week 216 | 0.00 (± 0.00) | 0.00 (± 0.00) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Zarit Burden Interview (ZBI) Scores at 24 Week Intervals During the DB Period

| | |
|-----------------|---|
| End point title | Change from Baseline in Zarit Burden Interview (ZBI) Scores at 24 Week Intervals During the DB Period |
|-----------------|---|

End point description:

The ZBI is the measurement to assess caregiver burden. The 22 items ask for the strain caregivers perceive. Responses range from 0 (never) to 4 (nearly always). The overall ZBI score ranges from 0 to 88. The higher the total score, the heavier the perceived burden. A negative change from baseline indicates an improvement.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Week 168

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|--------------------------------------|------------------------------|-----------------------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 13 | | |
| Units: score on scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 19.31 (± 9.31) | 18.92 (± 12.82) | | |
| Change from Baseline at Week 24 | -3.44 (± 5.59) | -3.57 (± 7.11) | | |
| Change from Baseline at Week 48 | 1.17 (± 8.26) | 1.13 (± 13.45) | | |
| Change from Baseline at Week 72 | 2.20 (± 19.64) | -0.71 (± 11.60) | | |
| Change from Baseline at Week 96 | 3.00 (± 14.98) | 4.17 (± 13.33) | | |
| Change from Baseline at Week 120 | 0.00 (± 3.61) | 3.40 (± 9.29) | | |
| Change from Baseline at Week 144 | -3.50 (± 12.02) | -3.50 (± 11.33) | | |
| Change from Baseline at Week 168 | 2.50 (± 13.44) | 11.00 (± 0000) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Expanded Disability Status Scale (EDSS) Scores at 24 Week Intervals During the DB Period

| | |
|-----------------|--|
| End point title | Change from Baseline in Expanded Disability Status Scale (EDSS) Scores at 24 Week Intervals During the DB Period |
|-----------------|--|

End point description:

The EDSS is an ordinal scale with values from 0 points (normal neurological examination) to 10 points (death) increasing in half-point increments once an EDSS of 1.0 has been reached. Higher scores represent increased disability. A negative change from baseline indicates an improvement.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Week 216

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|--------------------------------------|------------------------------|-----------------------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 41 | 41 | | |
| Units: score on scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 3.63 (± 1.32) | 3.83 (± 1.57) | | |
| Change from Baseline at Week 24 | -0.21 (± 0.68) | -0.14 (± 0.82) | | |
| Change from Baseline at Week 48 | -0.19 (± 0.77) | -0.19 (± 0.67) | | |
| Change from Baseline at Week 72 | -0.27 (± 0.68) | -0.29 (± 0.73) | | |
| Change from Baseline at Week 96 | -0.19 (± 0.81) | -0.19 (± 0.75) | | |
| Change from Baseline at Week 120 | -0.30 (± 0.79) | 0.03 (± 0.57) | | |
| Change from Baseline at Week 144 | -0.33 (± 0.83) | -0.07 (± 0.62) | | |
| Change from Baseline at Week 168 | -0.17 (± 0.76) | -0.06 (± 0.58) | | |

| | | | | |
|----------------------------------|--------------------|---------------------|--|--|
| Change from Baseline at Week 192 | 0000 (\pm 0000) | 0.00 (\pm 0.71) | | |
| Change from Baseline at Week 216 | 0000 (\pm 0000) | -0.50 (\pm 0000) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Visual Acuity (Snellen Chart) at 24 Week Intervals During the DB Period

| | |
|-----------------|---|
| End point title | Change from Baseline in Visual Acuity (Snellen Chart) at 24 Week Intervals During the DB Period |
|-----------------|---|

End point description:

Visual acuity was measured using Snellen 20-foot wall chart and then converted to logMAR visual acuity scoring. Lower values indicate better visual acuity. Data are reported for right eye (OD) and left eye (OS). A negative change from baseline indicates an improvement.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Week 216

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|--------------------------------------|------------------------------|-----------------------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: LogMAR units | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline: OD | 0.490 (\pm 0.928) | 0.303 (\pm 0.593) | | |
| Baseline: OS | 0.526 (\pm 0.911) | 0.597 (\pm 1.016) | | |
| Change from Baseline at Week 24: OD | -0.064 (\pm 0.197) | 0.042 (\pm 0.236) | | |
| Change from Baseline at Week 24: OS | -0.012 (\pm 0.107) | 0.059 (\pm 0.319) | | |
| Change from Baseline at Week 48: OD | -0.019 (\pm 0.086) | 0.008 (\pm 0.093) | | |
| Change from Baseline at Week 48: OS | 0.026 (\pm 0.096) | 0.013 (\pm 0.061) | | |
| Change from Baseline at Week 72: OD | -0.001 (\pm 0.110) | -0.034 (\pm 0.111) | | |
| Change from Baseline at Week 72: OS | -0.001 (\pm 0.121) | -0.019 (\pm 0.077) | | |
| Change from Baseline at Week 96: OD | 0.018 (\pm 0.174) | -0.013 (\pm 0.095) | | |
| Change from Baseline at Week 96: OS | -0.078 (\pm 0.185) | -0.010 (\pm 0.073) | | |
| Change from Baseline at Week 120: OD | 0.030 (\pm 0.150) | 0.011 (\pm 0.103) | | |
| Change from Baseline at Week 120: OS | -0.024 (\pm 0.150) | 0.014 (\pm 0.257) | | |

| | | | | |
|--------------------------------------|------------------|------------------|--|--|
| Change from Baseline at Week 144: OD | 0.058 (± 0.231) | -0.016 (± 0.120) | | |
| Change from Baseline at Week 144: OS | -0.016 (± 0.165) | -0.028 (± 0.111) | | |
| Change from Baseline at Week 168: OD | 0.113 (± 0.306) | 0.027 (± 0.199) | | |
| Change from Baseline at Week 168: OS | 0.100 (± 0.173) | -0.024 (± 0.113) | | |
| Change from Baseline at Week 192: OD | 0.000 (± 0.000) | 0.150 (± 0.099) | | |
| Change from Baseline at Week 192: OS | 0.000 (± 0.000) | 0.000 (± 0.000) | | |
| Change from Baseline at Week 216: OD | 0.000 (± 0.000) | 0.120 (± 0.000) | | |
| Change from Baseline at Week 216: OS | 0.000 (± 0.000) | 0.000 (± 0.000) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Short Form Generic Health Survey (SF-36) Mental Component Summary Scores at 24 Week Intervals During the DB Period

| | |
|-----------------|--|
| End point title | Change from Baseline in Short Form Generic Health Survey (SF-36) Mental Component Summary Scores at 24 Week Intervals During the DB Period |
|-----------------|--|

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health summary measures and a preference-based health utility index. The component scores were transformed to a 0-100 scale, where higher score indicates better quality of life. A positive change from baseline indicates an improvement.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Week 216

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|--------------------------------------|------------------------------|-----------------------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: score on scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 44.77 (± 11.08) | 44.56 (± 9.75) | | |
| Change from Baseline at Week 24 | 2.53 (± 7.58) | 0.57 (± 8.99) | | |
| Change from Baseline at Week 48 | 2.78 (± 7.51) | -0.61 (± 10.97) | | |
| Change from Baseline at Week 72 | 3.47 (± 7.13) | 2.78 (± 8.13) | | |
| Change from Baseline at Week 96 | 5.16 (± 10.52) | 1.06 (± 7.63) | | |
| Change from Baseline at Week 120 | 3.63 (± 8.62) | 0.71 (± 7.23) | | |
| Change from Baseline at Week 144 | 2.83 (± 8.79) | 3.82 (± 7.15) | | |
| Change from Baseline at Week 168 | 2.79 (± 6.85) | 3.60 (± 9.50) | | |

| | | | | |
|----------------------------------|---------------|----------------|--|--|
| Change from Baseline at Week 192 | 0000 (± 0000) | 11.60 (± 7.32) | | |
| Change from Baseline at Week 216 | 0000 (± 0000) | 14.05 (± 0000) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in SF-36 Physical Component Summary Scores at 24 Week Intervals During the DB Period

| | |
|---|---|
| End point title | Change from Baseline in SF-36 Physical Component Summary Scores at 24 Week Intervals During the DB Period |
| End point description: The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health summary measures and a preference-based health utility index. The component scores were transformed to a 0-100 scale, where higher score indicates better quality of life. A positive change from baseline indicates an improvement. | |
| End point type | Secondary |
| End point timeframe: Baseline up to Week 216 | |

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|--------------------------------------|------------------------------------|---|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: score on scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 41.54 (± 9.11) | 43.60 (± 10.47) | | |
| Change from Baseline at Week 24 | 2.79 (± 5.61) | 1.30 (± 6.01) | | |
| Change from Baseline at Week 48 | 0.18 (± 5.33) | 1.22 (± 5.77) | | |
| Change from Baseline at Week 72 | 1.97 (± 6.23) | 1.16 (± 4.79) | | |
| Change from Baseline at Week 96 | -1.15 (± 7.52) | 1.88 (± 5.72) | | |
| Change from Baseline at Week 120 | -0.13 (± 7.10) | 2.34 (± 6.60) | | |
| Change from Baseline at Week 144 | 1.78 (± 5.50) | 3.05 (± 4.23) | | |
| Change from Baseline at Week 168 | 0.22 (± 9.23) | 0.76 (± 5.98) | | |
| Change from Baseline at Week 192 | 0000 (± 0000) | 0.23 (± 0.55) | | |
| Change from Baseline at Week 216 | 0000 (± 0000) | -1.63 (± 0000) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in SF-36 Bodily Pain Domain Scores at 24 Week Intervals During the DB Period

| | |
|-----------------|---|
| End point title | Change from Baseline in SF-36 Bodily Pain Domain Scores at 24 Week Intervals During the DB Period |
|-----------------|---|

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Week 216

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|--------------------------------------|------------------------------|-----------------------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: score on scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 43.91 (± 10.22) | 45.94 (± 11.56) | | |
| Change from Baseline at Week 24 | 2.71 (± 7.06) | 0.03 (± 11.06) | | |
| Change from Baseline at Week 48 | 0.81 (± 5.60) | 0.12 (± 6.99) | | |
| Change from Baseline at Week 72 | 3.55 (± 8.20) | 2.30 (± 6.99) | | |
| Change from Baseline at Week 96 | 1.31 (± 7.13) | 1.15 (± 8.86) | | |
| Change from Baseline at Week 120 | 2.22 (± 9.96) | -1.45 (± 9.13) | | |
| Change from Baseline at Week 144 | 3.58 (± 8.53) | 3.14 (± 8.18) | | |
| Change from Baseline at Week 168 | 1.61 (± 10.58) | 3.05 (± 9.00) | | |
| Change from Baseline at Week 192 | 0000 (± 0000) | 8.07 (± 0.57) | | |
| Change from Baseline at Week 216 | 0000 (± 0000) | 3.63 (± 0000) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in SF-36 General Health Domain Scores at 24 Week Intervals During the DB Period

| | |
|-----------------|--|
| End point title | Change from Baseline in SF-36 General Health Domain Scores at 24 Week Intervals During the DB Period |
|-----------------|--|

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:
Baseline up to Week 216

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|--------------------------------------|------------------------------------|---|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: score on scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 39.65 (± 7.90) | 41.23 (± 9.29) | | |
| Change from Baseline at Week 24 | 1.84 (± 5.68) | -0.60 (± 7.26) | | |
| Change from Baseline at Week 48 | -0.66 (± 5.53) | -0.27 (± 6.00) | | |
| Change from Baseline at Week 72 | -0.16 (± 6.25) | 0.94 (± 5.57) | | |
| Change from Baseline at Week 96 | -1.90 (± 6.17) | 1.86 (± 6.12) | | |
| Change from Baseline at Week 120 | -0.33 (± 4.03) | 3.76 (± 6.72) | | |
| Change from Baseline at Week 144 | -0.95 (± 5.66) | 5.20 (± 7.11) | | |
| Change from Baseline at Week 168 | -5.23 (± 7.41) | 3.06 (± 6.99) | | |
| Change from Baseline at Week 192 | 0000 (± 0000) | 1.19 (± 5.04) | | |
| Change from Baseline at Week 216 | 0000 (± 0000) | -2.38 (± 0000) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in SF-36 Mental Health Domain Scores at 24 Week Intervals During the DB Period

| | |
|-----------------|---|
| End point title | Change from Baseline in SF-36 Mental Health Domain Scores at 24 Week Intervals During the DB Period |
|-----------------|---|

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Week 216

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|--------------------------------------|------------------------------|-----------------------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: score on scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 43.71 (\pm 10.92) | 43.59 (\pm 10.55) | | |
| Change from Baseline at Week 24 | 5.23 (\pm 7.69) | 0.99 (\pm 10.21) | | |
| Change from Baseline at Week 48 | 2.76 (\pm 8.54) | 0.11 (\pm 10.73) | | |
| Change from Baseline at Week 72 | 5.23 (\pm 7.66) | 3.18 (\pm 9.72) | | |
| Change from Baseline at Week 96 | 4.09 (\pm 8.49) | 2.12 (\pm 8.13) | | |
| Change from Baseline at Week 120 | 3.14 (\pm 7.06) | 1.57 (\pm 6.76) | | |
| Change from Baseline at Week 144 | 3.49 (\pm 7.04) | 4.88 (\pm 8.38) | | |
| Change from Baseline at Week 168 | 4.36 (\pm 3.02) | 4.07 (\pm 10.72) | | |
| Change from Baseline at Week 192 | 0000 (\pm 0000) | 13.09 (\pm 14.80) | | |
| Change from Baseline at Week 216 | 0000 (\pm 0000) | 23.55 (\pm 0000) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in SF-36 Physical Functioning Domain Scores at 24 Week Intervals During the DB Period

| | |
|-----------------|--|
| End point title | Change from Baseline in SF-36 Physical Functioning Domain Scores at 24 Week Intervals During the DB Period |
|-----------------|--|

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Week 216

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|--------------------------------------|------------------------------|-----------------------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: score on scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 42.50 (\pm 10.53) | 43.46 (\pm 10.34) | | |
| Change from Baseline at Week 24 | 3.56 (\pm 7.04) | 1.49 (\pm 7.05) | | |
| Change from Baseline at Week 48 | 1.92 (\pm 4.30) | 1.86 (\pm 7.73) | | |

| | | | | |
|----------------------------------|----------------|---------------|--|--|
| Change from Baseline at Week 72 | 3.19 (± 6.54) | 0.88 (± 6.52) | | |
| Change from Baseline at Week 96 | 0.84 (± 6.77) | 2.37 (± 7.75) | | |
| Change from Baseline at Week 120 | -0.19 (± 8.39) | 2.58 (± 6.03) | | |
| Change from Baseline at Week 144 | 2.55 (± 4.06) | 3.32 (± 5.72) | | |
| Change from Baseline at Week 168 | 1.92 (± 5.06) | 0.00 (± 5.50) | | |
| Change from Baseline at Week 192 | 0000 (± 0000) | 1.91 (± 2.70) | | |
| Change from Baseline at Week 216 | 0000 (± 0000) | 1.91 (± 0000) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in SF-36 Role-Emotional Domain Scores at 24 Week Intervals During the DB Period

| | |
|-----------------|--|
| End point title | Change from Baseline in SF-36 Role-Emotional Domain Scores at 24 Week Intervals During the DB Period |
|-----------------|--|

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Week 216

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|--------------------------------------|------------------------------|-----------------------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: score on scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 43.98 (± 11.46) | 43.01 (± 10.55) | | |
| Change from Baseline at Week 24 | 2.24 (± 10.35) | 0.36 (± 10.12) | | |
| Change from Baseline at Week 48 | 3.29 (± 8.05) | 0.00 (± 12.49) | | |
| Change from Baseline at Week 72 | 1.39 (± 9.38) | 2.57 (± 7.66) | | |
| Change from Baseline at Week 96 | 4.13 (± 14.40) | 0.83 (± 10.20) | | |
| Change from Baseline at Week 120 | 3.13 (± 12.44) | 0.35 (± 6.95) | | |
| Change from Baseline at Week 144 | 3.09 (± 9.61) | 3.25 (± 7.38) | | |
| Change from Baseline at Week 168 | 1.16 (± 5.32) | 4.64 (± 9.05) | | |
| Change from Baseline at Week 192 | 0000 (± 0000) | 12.19 (± 2.46) | | |
| Change from Baseline at Week 216 | 0000 (± 0000) | 6.97 (± 0000) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in SF-36 Role-Physical Domain Scores at 24 Week Intervals During the DB Period

| | |
|-----------------|---|
| End point title | Change from Baseline in SF-36 Role-Physical Domain Scores at 24 Week Intervals During the DB Period |
|-----------------|---|

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Week 216

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|--------------------------------------|------------------------------------|---|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: score on scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 40.74 (± 10.12) | 41.88 (± 11.38) | | |
| Change from Baseline at Week 24 | 3.93 (± 9.56) | 3.02 (± 6.95) | | |
| Change from Baseline at Week 48 | 1.37 (± 7.23) | 1.40 (± 8.66) | | |
| Change from Baseline at Week 72 | 2.40 (± 7.94) | 2.83 (± 7.81) | | |
| Change from Baseline at Week 96 | 0.42 (± 9.03) | 1.71 (± 4.60) | | |
| Change from Baseline at Week 120 | 1.57 (± 9.47) | 3.14 (± 7.44) | | |
| Change from Baseline at Week 144 | 2.99 (± 6.05) | 2.69 (± 6.80) | | |
| Change from Baseline at Week 168 | 3.74 (± 10.61) | 2.25 (± 6.45) | | |
| Change from Baseline at Week 192 | 0000 (± 0000) | 4.49 (± 6.35) | | |
| Change from Baseline at Week 216 | 0000 (± 0000) | 8.98 (± 0000) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in SF-36 Social Role Functioning Domain Scores at 24 Week Intervals During the DB Period

| | |
|-----------------|---|
| End point title | Change from Baseline in SF-36 Social Role Functioning Domain Scores at 24 Week Intervals During the DB Period |
|-----------------|---|

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The

domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement.

| | |
|-------------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Baseline up to Week 216 | |

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|--------------------------------------|------------------------------------|---|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: score on scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 41.70 (± 11.62) | 44.26 (± 10.92) | | |
| Change from Baseline at Week 24 | 1.73 (± 7.96) | 0.86 (± 8.69) | | |
| Change from Baseline at Week 48 | 1.12 (± 7.80) | 0.00 (± 10.24) | | |
| Change from Baseline at Week 72 | 2.34 (± 7.78) | 2.18 (± 7.22) | | |
| Change from Baseline at Week 96 | 2.82 (± 11.72) | 0.00 (± 9.38) | | |
| Change from Baseline at Week 120 | 1.51 (± 13.59) | 0.25 (± 9.13) | | |
| Change from Baseline at Week 144 | 0.56 (± 9.85) | 2.01 (± 7.29) | | |
| Change from Baseline at Week 168 | 1.67 (± 22.61) | 0.00 (± 5.61) | | |
| Change from Baseline at Week 192 | 0000 (± 0000) | 0.00 (± 0.00) | | |
| Change from Baseline at Week 216 | 0000 (± 0000) | -5.01 (± 0000) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in SF-36 Vitality Domain Scores at 24 Week Intervals During the DB Period

| | |
|--|--|
| End point title | Change from Baseline in SF-36 Vitality Domain Scores at 24 Week Intervals During the DB Period |
| End point description: | |
| The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline up to Week 216 | |

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|--------------------------------------|------------------------------|-----------------------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: score on scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 45.95 (± 9.14) | 46.66 (± 9.65) | | |
| Change from Baseline at Week 24 | 2.66 (± 7.38) | 1.74 (± 8.61) | | |
| Change from Baseline at Week 48 | 1.65 (± 5.60) | -0.25 (± 8.71) | | |
| Change from Baseline at Week 72 | 4.55 (± 6.91) | 1.38 (± 9.12) | | |
| Change from Baseline at Week 96 | 4.08 (± 8.53) | 2.41 (± 8.28) | | |
| Change from Baseline at Week 120 | 2.97 (± 5.24) | 2.67 (± 8.45) | | |
| Change from Baseline at Week 144 | 3.96 (± 6.12) | 4.16 (± 10.03) | | |
| Change from Baseline at Week 168 | 2.97 (± 2.97) | 0.99 (± 10.82) | | |
| Change from Baseline at Week 192 | 0000 (± 0000) | 7.43 (± 10.51) | | |
| Change from Baseline at Week 216 | 0000 (± 0000) | 11.89 (± 0000) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in EuroQoL-5 Dimensions (EQ-5D) Index Scores at 24 Week Intervals During the DB Period

| | |
|-------------------------|---|
| End point title | Change from Baseline in EuroQoL-5 Dimensions (EQ-5D) Index Scores at 24 Week Intervals During the DB Period |
| End point description: | The EQ-5D is a participant-answered questionnaire measuring 5 dimensions of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression with 3 possible response categories: 1) no problems; 2) some problems; 3) severe problems. The scores from 5 dimensions are used as input to generate EQ-5D index score using scoring algorithm. The EQ-5D index score is scored on a scale of -0.2 to 1. A higher score reflects a better health state. A positive change from baseline indicates an improvement. |
| End point type | Secondary |
| End point timeframe: | |
| Baseline up to Week 216 | |

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|--------------------------------------|------------------------------|-----------------------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 40 | | |
| Units: score on scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 0.7297 (± 0.1863) | 0.7634 (± 0.1811) | | |
| Change from Baseline at Week 24 | 0.0649 (± 0.1596) | -0.0082 (± 0.1882) | | |
| Change from Baseline at Week 48 | 0.0352 (± 0.1830) | 0.0011 (± 0.1256) | | |

| | | | | |
|----------------------------------|-------------------|-------------------|--|--|
| Change from Baseline at Week 72 | 0.0724 (± 0.2088) | 0.0241 (± 0.1084) | | |
| Change from Baseline at Week 96 | 0.0349 (± 0.1758) | 0.0167 (± 0.1056) | | |
| Change from Baseline at Week 120 | 0.0336 (± 0.2111) | 0.0257 (± 0.1178) | | |
| Change from Baseline at Week 144 | 0.0846 (± 0.1650) | 0.0488 (± 0.1424) | | |
| Change from Baseline at Week 168 | 0.0648 (± 0.1031) | 0.0307 (± 0.1335) | | |
| Change from Baseline at Week 192 | 0000 (± 0000) | 0.1873 (± 0.2890) | | |
| Change from Baseline at Week 216 | 0000 (± 0000) | 0.3322 (± 0000) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Serum Satralizumab Concentration During the DB Period

| | |
|--|---|
| End point title | Serum Satralizumab Concentration During the DB Period |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline, Weeks 2, 4, 5, 6, 8, and every 4 weeks thereafter up to Week 224 | |

| End point values | Satralizumab + Baseline Treatment | | | |
|--------------------------------------|-----------------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 41 | | | |
| Units: ng/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 100.00 (± 0.00) | | | |
| Week 2 | 11343.66 (± 5125.84) | | | |
| Week 4 | 22222.63 (± 8003.48) | | | |
| Week 5 | 28461.00 (± 12542.52) | | | |
| Week 6 | 28174.50 (± 11199.00) | | | |
| Week 8 | 21246.92 (± 9045.31) | | | |
| Week 12 | 20927.63 (± 9536.07) | | | |
| Week 16 | 20274.86 (± 10694.38) | | | |
| Week 20 | 20146.06 (± 10740.65) | | | |

| | | | | |
|----------|----------------------------|--|--|--|
| Week 24 | 20189.00 (\pm 10140.88) | | | |
| Week 28 | 20826.07 (\pm 10995.92) | | | |
| Week 32 | 20631.79 (\pm 11110.94) | | | |
| Week 36 | 21114.62 (\pm 11190.52) | | | |
| Week 40 | 22224.76 (\pm 13389.71) | | | |
| Week 44 | 22582.17 (\pm 12031.13) | | | |
| Week 48 | 23324.80 (\pm 13979.87) | | | |
| Week 52 | 24570.83 (\pm 15798.38) | | | |
| Week 56 | 24252.50 (\pm 15433.80) | | | |
| Week 60 | 23061.67 (\pm 15777.82) | | | |
| Week 64 | 23369.55 (\pm 13447.96) | | | |
| Week 68 | 26194.43 (\pm 16836.77) | | | |
| Week 72 | 26618.87 (\pm 14999.38) | | | |
| Week 76 | 26539.09 (\pm 13736.30) | | | |
| Week 80 | 26868.00 (\pm 14005.87) | | | |
| Week 84 | 27037.62 (\pm 15460.97) | | | |
| Week 88 | 26203.00 (\pm 14309.81) | | | |
| Week 92 | 28308.10 (\pm 15111.34) | | | |
| Week 96 | 26754.43 (\pm 15146.20) | | | |
| Week 100 | 27707.14 (\pm 14225.93) | | | |
| Week 104 | 26203.81 (\pm 13616.28) | | | |
| Week 108 | 26112.38 (\pm 12521.65) | | | |
| Week 112 | 24925.10 (\pm 12181.81) | | | |
| Week 116 | 26360.50 (\pm 13885.76) | | | |
| Week 120 | 24910.00 (\pm 13217.57) | | | |
| Week 124 | 24689.50 (\pm 14352.30) | | | |
| Week 128 | 22395.53 (\pm 12954.00) | | | |
| Week 132 | 23804.74 (\pm 14878.32) | | | |
| Week 136 | 25856.32 (\pm 15506.85) | | | |
| Week 140 | 26118.56 (\pm 15264.89) | | | |
| Week 144 | 27975.33 (\pm 11536.28) | | | |

| | | | | |
|----------|-----------------------|--|--|--|
| Week 148 | 27935.83 (± 11940.90) | | | |
| Week 152 | 28967.00 (± 10354.22) | | | |
| Week 156 | 27990.00 (± 10444.75) | | | |
| Week 160 | 28983.33 (± 11429.02) | | | |
| Week 164 | 28903.33 (± 10780.69) | | | |
| Week 168 | 23683.33 (± 11615.40) | | | |
| Week 172 | 24498.89 (± 11106.23) | | | |
| Week 176 | 26300.00 (± 11498.48) | | | |
| Week 180 | 28300.00 (± 9431.86) | | | |
| Week 184 | 32380.00 (± 9427.19) | | | |
| Week 188 | 36600.00 (± 8214.62) | | | |
| Week 192 | 32650.00 (± 7848.89) | | | |
| Week 196 | 30800.00 (± 4808.33) | | | |
| Week 200 | 28400.00 (± 3818.38) | | | |
| Week 204 | 25300.00 (± 3252.69) | | | |
| Week 208 | 25900.00 (± 0000) | | | |
| Week 212 | 17000.00 (± 0000) | | | |
| Week 216 | 28600.00 (± 0000) | | | |
| Week 220 | 31600.00 (± 0000) | | | |
| Week 224 | 28700.00 (± 0000) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Serum Soluble IL-6 Receptor (sIL-6R) Concentration During the DB Period

| | |
|-----------------|---|
| End point title | Serum Soluble IL-6 Receptor (sIL-6R) Concentration During the DB Period |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 2, 4, and every 4 weeks thereafter up to Week 224

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|--------------------------------------|------------------------------------|---|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: ng/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 32.52 (± 7.78) | 35.13 (± 21.52) | | |
| Week 2 | 33.82 (± 8.30) | 437.41 (± 72.31) | | |
| Week 4 | 33.13 (± 8.52) | 572.29 (± 94.84) | | |
| Week 8 | 34.02 (± 9.43) | 642.92 (± 115.51) | | |
| Week 12 | 32.58 (± 8.52) | 651.41 (± 99.20) | | |
| Week 16 | 32.67 (± 9.32) | 640.57 (± 97.41) | | |
| Week 20 | 34.22 (± 8.15) | 636.64 (± 109.75) | | |
| Week 24 | 34.44 (± 9.31) | 639.20 (± 108.94) | | |
| Week 28 | 33.70 (± 8.28) | 649.11 (± 131.85) | | |
| Week 32 | 33.48 (± 8.74) | 651.82 (± 162.04) | | |
| Week 36 | 34.39 (± 11.01) | 652.12 (± 124.70) | | |
| Week 40 | 33.31 (± 7.86) | 664.21 (± 158.61) | | |
| Week 44 | 33.94 (± 7.77) | 677.13 (± 173.99) | | |
| Week 48 | 34.50 (± 9.14) | 627.23 (± 217.06) | | |
| Week 52 | 44.01 (± 44.26) | 656.29 (± 173.67) | | |
| Week 56 | 37.00 (± 7.42) | 626.83 (± 155.56) | | |
| Week 60 | 36.39 (± 7.81) | 617.00 (± 142.13) | | |
| Week 64 | 35.14 (± 8.78) | 621.27 (± 152.45) | | |
| Week 68 | 35.35 (± 8.68) | 664.91 (± 130.58) | | |
| Week 72 | 36.02 (± 10.73) | 648.83 (± 134.32) | | |
| Week 76 | 36.94 (± 9.46) | 643.91 (± 118.60) | | |
| Week 80 | 36.45 (± 9.50) | 667.24 (± 133.49) | | |
| Week 84 | 34.60 (± 8.88) | 649.38 (± 137.64) | | |
| Week 88 | 31.95 (± 8.29) | 651.35 (± 150.58) | | |
| Week 92 | 34.30 (± 9.71) | 633.43 (± 134.36) | | |

| | | | | |
|----------|-----------------|-------------------|--|--|
| Week 96 | 32.88 (± 9.39) | 630.62 (± 162.28) | | |
| Week 100 | 33.78 (± 9.04) | 651.90 (± 162.09) | | |
| Week 104 | 31.61 (± 9.13) | 649.57 (± 185.99) | | |
| Week 108 | 31.49 (± 9.23) | 658.67 (± 152.61) | | |
| Week 112 | 32.75 (± 7.77) | 683.90 (± 135.07) | | |
| Week 116 | 33.68 (± 8.31) | 653.98 (± 194.92) | | |
| Week 120 | 33.73 (± 6.20) | 667.10 (± 152.24) | | |
| Week 124 | 33.06 (± 9.31) | 696.45 (± 138.17) | | |
| Week 128 | 34.07 (± 8.83) | 670.05 (± 138.28) | | |
| Week 132 | 34.28 (± 4.95) | 671.84 (± 138.75) | | |
| Week 136 | 32.43 (± 8.12) | 674.95 (± 170.04) | | |
| Week 140 | 32.97 (± 6.52) | 645.72 (± 132.32) | | |
| Week 144 | 35.37 (± 8.91) | 699.80 (± 101.84) | | |
| Week 148 | 37.97 (± 12.40) | 672.42 (± 107.40) | | |
| Week 152 | 35.08 (± 9.08) | 701.60 (± 110.27) | | |
| Week 156 | 36.92 (± 7.77) | 720.33 (± 103.58) | | |
| Week 160 | 40.38 (± 7.31) | 704.89 (± 109.86) | | |
| Week 164 | 43.08 (± 10.54) | 723.67 (± 136.20) | | |
| Week 168 | 42.30 (± 5.92) | 744.22 (± 123.47) | | |
| Week 172 | 42.03 (± 5.87) | 706.33 (± 127.63) | | |
| Week 176 | 39.85 (± 6.15) | 730.56 (± 121.75) | | |
| Week 180 | 38.85 (± 12.09) | 769.83 (± 119.50) | | |
| Week 184 | 0000 (± 0000) | 736.80 (± 152.09) | | |
| Week 188 | 0000 (± 0000) | 853.67 (± 38.02) | | |
| Week 192 | 0000 (± 0000) | 930.00 (± 49.50) | | |
| Week 196 | 0000 (± 0000) | 887.00 (± 91.92) | | |
| Week 200 | 0000 (± 0000) | 902.50 (± 79.90) | | |
| Week 204 | 0000 (± 0000) | 935.00 (± 7.07) | | |
| Week 208 | 0000 (± 0000) | 941.00 (± 0000) | | |
| Week 212 | 0000 (± 0000) | 971.00 (± 0000) | | |
| Week 216 | 0000 (± 0000) | 896.00 (± 0000) | | |

| | | | | |
|----------|---------------|-----------------|--|--|
| Week 220 | 0000 (± 0000) | 901.00 (± 0000) | | |
| Week 224 | 0000 (± 0000) | 831.00 (± 0000) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Serum High Sensitivity C-Reactive Protein (hsCRP) Concentration During the DB Period

| | |
|-----------------|--|
| End point title | Serum High Sensitivity C-Reactive Protein (hsCRP) Concentration During the DB Period |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 2, 4, and every 4 weeks thereafter up to Week 224

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|--------------------------------------|------------------------------|-----------------------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: mg/L | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 1.48 (± 2.08) | 1.68 (± 2.49) | | |
| Week 2 | 1.65 (± 2.86) | 0.78 (± 2.93) | | |
| Week 4 | 1.59 (± 2.27) | 0.44 (± 0.72) | | |
| Week 8 | 1.76 (± 2.25) | 0.59 (± 1.26) | | |
| Week 12 | 1.48 (± 2.07) | 0.47 (± 0.60) | | |
| Week 16 | 1.91 (± 3.34) | 0.49 (± 0.51) | | |
| Week 20 | 1.91 (± 3.44) | 0.48 (± 0.50) | | |
| Week 24 | 2.45 (± 6.87) | 0.58 (± 0.91) | | |
| Week 28 | 1.96 (± 3.24) | 0.73 (± 1.34) | | |
| Week 32 | 2.36 (± 4.96) | 0.73 (± 1.21) | | |
| Week 36 | 2.48 (± 3.59) | 0.56 (± 0.66) | | |
| Week 40 | 2.49 (± 4.53) | 1.13 (± 2.26) | | |
| Week 44 | 1.41 (± 1.47) | 0.72 (± 1.20) | | |
| Week 48 | 1.59 (± 2.07) | 0.86 (± 1.44) | | |
| Week 52 | 2.60 (± 3.87) | 0.67 (± 0.88) | | |
| Week 56 | 1.43 (± 1.58) | 0.72 (± 1.02) | | |
| Week 60 | 2.63 (± 4.34) | 1.05 (± 2.15) | | |
| Week 64 | 11.10 (± 40.09) | 0.64 (± 0.89) | | |
| Week 68 | 1.86 (± 2.66) | 0.57 (± 0.47) | | |
| Week 72 | 3.80 (± 8.83) | 0.59 (± 0.71) | | |
| Week 76 | 5.24 (± 10.68) | 0.51 (± 0.37) | | |

| | | | | |
|----------|-----------------|---------------|--|--|
| Week 80 | 2.11 (± 2.63) | 0.58 (± 0.51) | | |
| Week 84 | 2.08 (± 2.26) | 0.59 (± 0.61) | | |
| Week 88 | 5.19 (± 12.83) | 0.60 (± 0.53) | | |
| Week 92 | 2.07 (± 2.21) | 0.60 (± 0.70) | | |
| Week 96 | 2.92 (± 4.60) | 0.74 (± 1.01) | | |
| Week 100 | 2.58 (± 4.53) | 0.87 (± 1.49) | | |
| Week 104 | 1.41 (± 2.05) | 0.84 (± 1.40) | | |
| Week 108 | 1.93 (± 2.25) | 0.66 (± 0.58) | | |
| Week 112 | 1.54 (± 1.56) | 0.82 (± 0.87) | | |
| Week 116 | 2.39 (± 3.91) | 0.84 (± 1.26) | | |
| Week 120 | 1.53 (± 1.33) | 0.98 (± 1.58) | | |
| Week 124 | 1.43 (± 1.43) | 0.72 (± 0.67) | | |
| Week 128 | 6.00 (± 16.28) | 0.96 (± 1.29) | | |
| Week 132 | 1.08 (± 0.94) | 0.70 (± 0.84) | | |
| Week 136 | 1.43 (± 1.54) | 0.99 (± 1.68) | | |
| Week 140 | 1.15 (± 1.28) | 1.06 (± 2.25) | | |
| Week 144 | 0.82 (± 0.73) | 0.44 (± 0.37) | | |
| Week 148 | 1.29 (± 1.43) | 0.35 (± 0.18) | | |
| Week 152 | 1.08 (± 0.97) | 0.38 (± 0.23) | | |
| Week 156 | 1.52 (± 1.42) | 0.35 (± 0.18) | | |
| Week 160 | 0.83 (± 0.53) | 0.37 (± 0.22) | | |
| Week 164 | 3.18 (± 4.89) | 0.38 (± 0.20) | | |
| Week 168 | 0.80 (± 0.26) | 0.40 (± 0.19) | | |
| Week 172 | 1.37 (± 1.00) | 0.26 (± 0.17) | | |
| Week 176 | 0.95 (± 0.64) | 0.31 (± 0.19) | | |
| Week 180 | 30.15 (± 41.65) | 0.28 (± 0.15) | | |
| Week 184 | 0000 (± 0000) | 0.20 (± 0.11) | | |
| Week 188 | 0000 (± 0000) | 0.37 (± 0.06) | | |
| Week 192 | 0000 (± 0000) | 0.15 (± 0.00) | | |
| Week 196 | 0000 (± 0000) | 0.23 (± 0.11) | | |
| Week 200 | 0000 (± 0000) | 0.23 (± 0.11) | | |
| Week 204 | 0000 (± 0000) | 0.23 (± 0.11) | | |
| Week 208 | 0000 (± 0000) | 0.30 (± 0000) | | |
| Week 212 | 0000 (± 0000) | 0.40 (± 0000) | | |
| Week 216 | 0000 (± 0000) | 0.30 (± 0000) | | |
| Week 220 | 0000 (± 0000) | 0.40 (± 0000) | | |
| Week 224 | 0000 (± 0000) | 0.15 (± 0000) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Serum Interleukin-6 (IL-6) Concentration During the DB Period

| | |
|-----------------|---|
| End point title | Serum Interleukin-6 (IL-6) Concentration During the DB Period |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 2, 4, and every 4 weeks thereafter up to Week 224

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|--------------------------------------|------------------------------------|---|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: pg/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 1.63 (± 0.39) | 1.92 (± 1.36) | | |
| Week 2 | 1.84 (± 0.95) | 40.12 (± 118.83) | | |
| Week 4 | 2.33 (± 2.99) | 28.30 (± 31.31) | | |
| Week 8 | 1.69 (± 0.55) | 32.37 (± 77.99) | | |
| Week 12 | 1.71 (± 0.60) | 22.95 (± 20.55) | | |
| Week 16 | 1.84 (± 0.90) | 25.76 (± 30.85) | | |
| Week 20 | 2.99 (± 5.45) | 23.07 (± 15.37) | | |
| Week 24 | 2.02 (± 1.52) | 21.53 (± 17.91) | | |
| Week 28 | 1.95 (± 1.38) | 25.14 (± 24.27) | | |
| Week 32 | 1.74 (± 0.84) | 23.77 (± 18.53) | | |
| Week 36 | 2.13 (± 1.41) | 23.08 (± 15.56) | | |
| Week 40 | 1.66 (± 0.40) | 27.31 (± 47.45) | | |
| Week 44 | 1.57 (± 0.00) | 17.01 (± 15.38) | | |
| Week 48 | 1.69 (± 0.53) | 19.45 (± 19.36) | | |
| Week 52 | 2.12 (± 1.36) | 21.11 (± 17.42) | | |
| Week 56 | 1.57 (± 0.00) | 21.74 (± 20.96) | | |
| Week 60 | 2.27 (± 1.46) | 23.25 (± 23.36) | | |
| Week 64 | 2.46 (± 3.22) | 24.31 (± 20.74) | | |
| Week 68 | 1.94 (± 1.14) | 31.30 (± 53.79) | | |
| Week 72 | 1.93 (± 0.97) | 24.69 (± 24.45) | | |
| Week 76 | 2.21 (± 1.87) | 20.45 (± 13.79) | | |
| Week 80 | 2.19 (± 2.51) | 23.29 (± 19.64) | | |
| Week 84 | 2.66 (± 2.36) | 22.71 (± 21.49) | | |
| Week 88 | 2.59 (± 2.77) | 29.17 (± 25.58) | | |

| | | | | |
|----------|---------------|-----------------|--|--|
| Week 92 | 1.84 (± 0.77) | 24.51 (± 32.02) | | |
| Week 96 | 3.06 (± 3.19) | 21.52 (± 20.20) | | |
| Week 100 | 2.04 (± 1.02) | 21.77 (± 24.98) | | |
| Week 104 | 1.95 (± 0.96) | 22.61 (± 26.55) | | |
| Week 108 | 1.76 (± 0.70) | 24.18 (± 20.55) | | |
| Week 112 | 1.57 (± 0.00) | 32.18 (± 36.15) | | |
| Week 116 | 1.57 (± 0.00) | 22.33 (± 22.20) | | |
| Week 120 | 1.71 (± 0.52) | 21.86 (± 24.54) | | |
| Week 124 | 1.57 (± 0.00) | 26.23 (± 27.67) | | |
| Week 128 | 1.57 (± 0.00) | 25.40 (± 31.20) | | |
| Week 132 | 1.57 (± 0.00) | 25.48 (± 27.38) | | |
| Week 136 | 1.57 (± 0.00) | 27.23 (± 37.56) | | |
| Week 140 | 1.57 (± 0.00) | 20.66 (± 18.10) | | |
| Week 144 | 1.57 (± 0.00) | 16.82 (± 16.16) | | |
| Week 148 | 2.04 (± 1.25) | 17.10 (± 11.33) | | |
| Week 152 | 1.57 (± 0.00) | 16.62 (± 13.75) | | |
| Week 156 | 2.34 (± 1.72) | 12.67 (± 5.73) | | |
| Week 160 | 1.96 (± 0.80) | 11.15 (± 5.12) | | |
| Week 164 | 1.57 (± 0.00) | 12.84 (± 6.93) | | |
| Week 168 | 1.57 (± 0.00) | 13.30 (± 8.89) | | |
| Week 172 | 1.57 (± 0.00) | 13.89 (± 6.94) | | |
| Week 176 | 1.57 (± 0.00) | 15.11 (± 7.16) | | |
| Week 180 | 1.57 (± 0.00) | 13.34 (± 6.68) | | |
| Week 184 | 0000 (± 0000) | 15.24 (± 9.91) | | |
| Week 188 | 0000 (± 0000) | 13.96 (± 9.74) | | |
| Week 192 | 0000 (± 0000) | 16.71 (± 13.15) | | |
| Week 196 | 0000 (± 0000) | 14.34 (± 12.81) | | |
| Week 200 | 0000 (± 0000) | 18.55 (± 8.84) | | |
| Week 204 | 0000 (± 0000) | 18.24 (± 12.53) | | |
| Week 208 | 0000 (± 0000) | 9.95 (± 0000) | | |
| Week 212 | 0000 (± 0000) | 8.02 (± 0000) | | |
| Week 216 | 0000 (± 0000) | 6.45 (± 0000) | | |
| Week 220 | 0000 (± 0000) | 45.80 (± 0000) | | |
| Week 224 | 0000 (± 0000) | 34.30 (± 0000) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with at Least One Adverse Event in the DB Period

| | |
|---|---|
| End point title | Number of Participants with at Least One Adverse Event in the DB Period |
| End point description: An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as adverse events. | |
| End point type | Secondary |
| End point timeframe: Up to Week 224 | |

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|-----------------------------|------------------------------------|---|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: participants | 40 | 37 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with at Least One Serious Adverse Event in the DB Period

| | |
|--|---|
| End point title | Number of Participants with at Least One Serious Adverse Event in the DB Period |
| End point description: A serious adverse event is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is medically significant or requires intervention to prevent one or other of the outcomes listed above. | |
| End point type | Secondary |
| End point timeframe: Up to Week 224 | |

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|-----------------------------|------------------------------|-----------------------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: participants | 9 | 7 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Non-Serious Adverse Events of Special Interest in the DB Period

| | |
|--|---|
| End point title | Number of Participants with Non-Serious Adverse Events of Special Interest in the DB Period |
| End point description: | |
| Non-serious adverse events of special interest for this study included: 1) cases of an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in combination with either an elevated bilirubin or clinical jaundice, 2) suspected transmission of an infectious agent by the study treatment. | |
| End point type | Secondary |
| End point timeframe: | |
| Up to Week 224 | |

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|-----------------------------|------------------------------|-----------------------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: participants | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Selected Adverse Events in the DB Period

| | |
|--|--|
| End point title | Number of Participants with Selected Adverse Events in the DB Period |
| End point description: | |
| Selected adverse events for this study included: 1) non-serious infections that required treatments with intravenous (IV) antibiotic, antifungal, antiviral, 2) opportunistic infections that required treatments with oral antibiotics, antifungals, or antivirals, 3) injection-related reactions (IRRs; an AE which occurred within 24 hours after study treatment injection except where the event was not considered an allergic reaction), and 4) anaphylaxis (an acute allergic/hypersensitivity reaction). | |
| End point type | Secondary |
| End point timeframe: | |
| Up to Week 224 | |

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|---|------------------------------------|---|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 42 | 41 | | |
| Units: participants | | | | |
| Non serious Infections requiring IV treatment | 4 | 1 | | |
| Potential Opportunistic Infections | 5 | 4 | | |
| Injection Related Reactions | 2 | 5 | | |
| Anaphylaxis | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Suicidal Behaviors and Ideations Collected by Columbia-Suicide Severity Rating Scale in the DB Period

| | |
|-----------------|---|
| End point title | Number of Participants With Suicidal Behaviors and Ideations Collected by Columbia-Suicide Severity Rating Scale in the DB Period |
|-----------------|---|

End point description:

The Columbia-Suicide Severity Rating Scale (C-SSRS) is an assessment tool to evaluate suicidal ideation and behavior. Categories have binary responses (yes/no) and include: Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation or behavior is indicated by a "yes" answer to any of the listed categories. A score of 0 is assigned if no suicide risk is present. A score of 1 or higher indicates suicidal ideation or behavior.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Post-Baseline (up to Week 224)

| End point values | Placebo + Baseline Treatment | Satralizumab + Baseline Treatment | | |
|-----------------------------|------------------------------------|---|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 41 | 41 | | |
| Units: participants | | | | |
| Baseline | 5 | 12 | | |
| Post-Baseline | 2 | 3 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with Anti-Drug Antibodies to Satralizumab in the DB Period

| | |
|-----------------|---|
| End point title | Percentage of Participants with Anti-Drug Antibodies to Satralizumab in the DB Period |
|-----------------|---|

End point description:

Reported here is the percentage of participants with at least one positive anti-drug antibody measurement during the DB period.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to approximately Week 224

| End point values | Satralizumab + Baseline Treatment | | | |
|-----------------------------|-----------------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 41 | | | |
| Units: percentage | | | | |
| number (not applicable) | 41.5 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with Anti-Drug Antibodies to Satralizumab Overall S237 period

| | |
|-----------------|--|
| End point title | Percentage of Participants with Anti-Drug Antibodies to Satralizumab Overall S237 period |
|-----------------|--|

End point description:

Reported here is the percentage of participants with at least one positive anti-drug antibody measurement during Overall S237 period. Participants from SAF who received satralizumab were evaluated for this outcome measure. The SAF included all randomized participants who had received at least 1 dose of satralizumab or placebo. Data was summarized together for this outcome measure.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to approximately Week 368

| End point values | Satralizumab + Baseline Treatment | | | |
|-----------------------------------|-----------------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 75 | | | |
| Units: Percentage of participants | | | | |
| number (not applicable) | | | | |
| Treatment-Boosted ADA Patients | 2.7 | | | |

| | | | | |
|--------------------------------|------|--|--|--|
| Treatment-Induced ADA Patients | 44.0 | | | |
|--------------------------------|------|--|--|--|

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to clinical cut-off date, 23-Dec-2021

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 24.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|--|
| Reporting group title | Placebo + Baseline Treatment Double Blind Period |
|-----------------------|--|

Reporting group description:

Participants randomized to this arm for the double-blind period received placebo in addition to baseline treatment. The double-blind period ends when either the participant has a treated relapse or the total number of protocol-defined relapses confirmed by the Clinical Endpoint Committee (CEC) reaches 26.

| | |
|-----------------------|---|
| Reporting group title | Satralizumab + Baseline Treatment Double Blind period |
|-----------------------|---|

Reporting group description:

Participants randomized to this arm for the double-blind period received satralizumab in addition to baseline treatment. The double-blind period ends when either the participant has a treated relapse or the total number of protocol-defined relapses confirmed by the Clinical Endpoint Committee (CEC) reaches 26.

| | |
|-----------------------|--|
| Reporting group title | Placebo + Baseline Treatment Open Label Period |
|-----------------------|--|

Reporting group description:

In the open-label extension period, the participant received (with or without baseline treatment) an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter, with the last study drug administration on or before 31 December 2021.

| | |
|-----------------------|---|
| Reporting group title | Satralizumab + Baseline Treatment Open Label period |
|-----------------------|---|

Reporting group description:

In the open-label extension period, the participant received (with or without baseline treatment) an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter, with the last study drug administration on or before 31 December 2021.

| | |
|-----------------------|--------------------------------|
| Reporting group title | Satralizumab Open-Label Period |
|-----------------------|--------------------------------|

Reporting group description:

Participant was directly enrolled into the OLE to receive natalizumab. In the open-label extension period, the participant received (with or without baseline treatment) an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter.

| Serious adverse events | Placebo + Baseline Treatment Double Blind Period | Satralizumab + Baseline Treatment Double Blind period | Placebo + Baseline Treatment Open Label Period |
|---|--|---|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 9 / 42 (21.43%) | 9 / 42 (21.43%) | 5 / 32 (15.63%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Hepatic cancer | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 42 (2.38%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Breast cancer | | | |
| subjects affected / exposed | 1 / 42 (2.38%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colon cancer metastatic | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 1 / 32 (3.13%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Uterine leiomyoma | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 1 / 42 (2.38%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Femur fracture | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 1 / 42 (2.38%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal compression fracture | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 1 / 42 (2.38%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper limb fracture | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Forearm fracture | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |

| | | | |
|---|----------------|----------------|----------------|
| Tension headache | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 1 / 42 (2.38%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Parkinsonism | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neuromyelitis optica pseudo relapse | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Seizure | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 1 / 32 (3.13%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Leukopenia | | | |
| subjects affected / exposed | 1 / 42 (2.38%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anaemia macrocytic | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 1 / 42 (2.38%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lymphopenia | | | |
| subjects affected / exposed | 1 / 42 (2.38%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune thrombocytopenia | | | |
| subjects affected / exposed | 1 / 42 (2.38%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration | | | |

| | | | |
|---|----------------|----------------|----------------|
| site conditions | | | |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eye disorders | | | |
| Glaucoma | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Retinal vein thrombosis | | | |
| subjects affected / exposed | 1 / 42 (2.38%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cataract | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 1 / 42 (2.38%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 42 (2.38%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis acute | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 1 / 32 (3.13%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Cervical dysplasia | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 42 (0.00%) | 1 / 42 (2.38%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Uterine polyp | | | |
| subjects affected / exposed | 1 / 42 (2.38%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Suicide attempt | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 1 / 42 (2.38%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Dysuria | | | |
| subjects affected / exposed | 1 / 42 (2.38%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Systemic lupus erythematosus | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 1 / 32 (3.13%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lumbar spinal stenosis | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Appendicitis | | | |
| subjects affected / exposed | 1 / 42 (2.38%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cellulitis | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 1 / 32 (3.13%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Escherichia sepsis | | | |
| subjects affected / exposed | 1 / 42 (2.38%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatitis E | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 42 (2.38%) | 1 / 42 (2.38%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 1 / 42 (2.38%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 1 / 32 (3.13%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestine infection | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Septic endocarditis | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 1 / 32 (3.13%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Satralizumab + Baseline Treatment Open Label period | Satralizumab Open- Label Period | |
|---|---|------------------------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 8 / 39 (20.51%) | 1 / 1 (100.00%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | 0 | 0 | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Hepatic cancer | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Breast cancer | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colon cancer metastatic | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Uterine leiomyoma | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injury, poisoning and procedural complications | | | |
| Femur fracture | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal compression fracture | | | |

| | | | |
|---|----------------|---------------|--|
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Upper limb fracture | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Forearm fracture | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorders | | | |
| Tension headache | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Parkinsonism | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neuromyelitis optica pseudo relapse | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Seizure | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood and lymphatic system disorders | | | |
| Leukopenia | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anaemia macrocytic | | | |

| | | | |
|--|----------------|---------------|--|
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lymphopenia | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Immune thrombocytopenia | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Gait disturbance | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Eye disorders | | | |
| Glaucoma | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retinal vein thrombosis | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cataract | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|----------------|-----------------|--|
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 1 / 1 (100.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatitis acute | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Reproductive system and breast disorders | | | |
| Cervical dysplasia | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Uterine polyp | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Psychiatric disorders | | | |
| Suicide attempt | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal and urinary disorders | | | |
| Dysuria | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Systemic lupus erythematosus | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lumbar spinal stenosis | | | |

| | | | |
|---|----------------|---------------|--|
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Appendicitis | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Escherichia sepsis | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatitis E | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Influenza | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urosepsis | | | |

| | | | |
|---|----------------|---------------|--|
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Large intestine infection | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Septic endocarditis | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Placebo + Baseline Treatment Double Blind Period | Satralizumab + Baseline Treatment Double Blind period | Placebo + Baseline Treatment Open Label Period |
|---|--|---|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 37 / 42 (88.10%) | 35 / 42 (83.33%) | 30 / 32 (93.75%) |
| Vascular disorders | | | |
| Flushing | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 1 / 42 (2.38%) | 3 / 32 (9.38%) |
| occurrences (all) | 0 | 1 | 3 |
| Hypertension | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 3 / 42 (7.14%) | 1 / 32 (3.13%) |
| occurrences (all) | 0 | 4 | 2 |
| Hypotension | | | |
| subjects affected / exposed | 1 / 42 (2.38%) | 0 / 42 (0.00%) | 2 / 32 (6.25%) |
| occurrences (all) | 1 | 0 | 2 |
| General disorders and administration site conditions | | | |
| Fatigue | | | |
| subjects affected / exposed | 1 / 42 (2.38%) | 2 / 42 (4.76%) | 4 / 32 (12.50%) |
| occurrences (all) | 1 | 2 | 5 |
| Pyrexia | | | |
| subjects affected / exposed | 5 / 42 (11.90%) | 0 / 42 (0.00%) | 1 / 32 (3.13%) |
| occurrences (all) | 7 | 0 | 1 |

| | | | |
|---|---|---|---|
| Non-cardiac chest pain subjects affected / exposed occurrences (all) | 1 / 42 (2.38%) 1 | 0 / 42 (0.00%) 0 | 3 / 32 (9.38%) 5 |
| Immune system disorders Hypocomplementaemia subjects affected / exposed occurrences (all) | 0 / 42 (0.00%) 0 | 0 / 42 (0.00%) 0 | 0 / 32 (0.00%) 0 |
| Reproductive system and breast disorders Dysmenorrhoea subjects affected / exposed occurrences (all) | 0 / 42 (0.00%) 0 | 1 / 42 (2.38%) 1 | 0 / 32 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all) Oropharyngeal pain subjects affected / exposed occurrences (all) Rhinorrhoea subjects affected / exposed occurrences (all) | 2 / 42 (4.76%) 3 1 / 42 (2.38%) 1 1 / 42 (2.38%) 1 | 1 / 42 (2.38%) 2 3 / 42 (7.14%) 4 1 / 42 (2.38%) 1 | 3 / 32 (9.38%) 3 2 / 32 (6.25%) 2 0 / 32 (0.00%) 0 |
| Psychiatric disorders Anxiety subjects affected / exposed occurrences (all) Insomnia subjects affected / exposed occurrences (all) Depression subjects affected / exposed occurrences (all) | 1 / 42 (2.38%) 1 0 / 42 (0.00%) 0 1 / 42 (2.38%) 1 | 2 / 42 (4.76%) 2 1 / 42 (2.38%) 1 1 / 42 (2.38%) 1 | 2 / 32 (6.25%) 2 3 / 32 (9.38%) 3 2 / 32 (6.25%) 2 |
| Investigations Aspartate aminotransferase increased subjects affected / exposed occurrences (all) Lymphocyte count decreased | 3 / 42 (7.14%) 4 | 1 / 42 (2.38%) 1 | 0 / 32 (0.00%) 0 |

| | | | |
|--|----------------|----------------|----------------|
| subjects affected / exposed | 2 / 42 (4.76%) | 1 / 42 (2.38%) | 3 / 32 (9.38%) |
| occurrences (all) | 2 | 1 | 3 |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 2 / 42 (4.76%) | 1 / 42 (2.38%) | 1 / 32 (3.13%) |
| occurrences (all) | 2 | 1 | 2 |
| Blood fibrinogen decreased | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 2 / 42 (4.76%) | 1 / 42 (2.38%) | 1 / 32 (3.13%) |
| occurrences (all) | 3 | 1 | 1 |
| Blood fibrinogen increased | | | |
| subjects affected / exposed | 1 / 42 (2.38%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood pressure increased | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 2 / 42 (4.76%) | 2 / 32 (6.25%) |
| occurrences (all) | 0 | 2 | 6 |
| Prothrombin time prolonged | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| White blood cell count decreased | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 1 / 42 (2.38%) | 2 / 32 (6.25%) |
| occurrences (all) | 0 | 1 | 5 |
| Blood cholesterol increased | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 2 / 42 (4.76%) | 2 / 32 (6.25%) |
| occurrences (all) | 0 | 2 | 2 |
| Haemoglobin decreased | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 1 / 42 (2.38%) | 0 / 32 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Lymphocyte percentage decreased | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--|---------------------|---------------------|----------------------|
| Lymphocyte percentage increased subjects affected / exposed occurrences (all) | 0 / 42 (0.00%) 0 | 0 / 42 (0.00%) 0 | 0 / 32 (0.00%) 0 |
| Monocyte count increased subjects affected / exposed occurrences (all) | 0 / 42 (0.00%) 0 | 0 / 42 (0.00%) 0 | 0 / 32 (0.00%) 0 |
| Neutrophil count increased subjects affected / exposed occurrences (all) | 0 / 42 (0.00%) 0 | 0 / 42 (0.00%) 0 | 0 / 32 (0.00%) 0 |
| Neutrophil percentage increased subjects affected / exposed occurrences (all) | 0 / 42 (0.00%) 0 | 0 / 42 (0.00%) 0 | 0 / 32 (0.00%) 0 |
| Platelet count increased subjects affected / exposed occurrences (all) | 2 / 42 (4.76%) 2 | 0 / 42 (0.00%) 0 | 0 / 32 (0.00%) 0 |
| White blood cell count increased subjects affected / exposed occurrences (all) | 1 / 42 (2.38%) 1 | 0 / 42 (0.00%) 0 | 0 / 32 (0.00%) 0 |
| Injury, poisoning and procedural complications | | | |
| Fall subjects affected / exposed occurrences (all) | 2 / 42 (4.76%) 2 | 0 / 42 (0.00%) 0 | 1 / 32 (3.13%) 2 |
| Ligament sprain subjects affected / exposed occurrences (all) | 1 / 42 (2.38%) 1 | 1 / 42 (2.38%) 1 | 5 / 32 (15.63%) 5 |
| Thermal burn subjects affected / exposed occurrences (all) | 3 / 42 (7.14%) 3 | 1 / 42 (2.38%) 1 | 1 / 32 (3.13%) 1 |
| Rib fracture subjects affected / exposed occurrences (all) | 1 / 42 (2.38%) 1 | 1 / 42 (2.38%) 1 | 0 / 32 (0.00%) 0 |
| Nervous system disorders | | | |
| Dizziness subjects affected / exposed occurrences (all) | 1 / 42 (2.38%) 1 | 2 / 42 (4.76%) 3 | 2 / 32 (6.25%) 2 |
| Headache | | | |

| | | | |
|--|----------------------|------------------------|----------------------|
| subjects affected / exposed occurrences (all) | 4 / 42 (9.52%) 6 | 10 / 42 (23.81%) 28 | 5 / 32 (15.63%) 8 |
| Hypoaesthesia subjects affected / exposed occurrences (all) | 0 / 42 (0.00%) 0 | 1 / 42 (2.38%) 1 | 3 / 32 (9.38%) 6 |
| Paraesthesia subjects affected / exposed occurrences (all) | 1 / 42 (2.38%) 1 | 0 / 42 (0.00%) 0 | 2 / 32 (6.25%) 2 |
| Blood and lymphatic system disorders | | | |
| Anaemia subjects affected / exposed occurrences (all) | 5 / 42 (11.90%) 8 | 3 / 42 (7.14%) 3 | 2 / 32 (6.25%) 2 |
| Iron deficiency anaemia subjects affected / exposed occurrences (all) | 1 / 42 (2.38%) 1 | 2 / 42 (4.76%) 3 | 4 / 32 (12.50%) 4 |
| Leukopenia subjects affected / exposed occurrences (all) | 4 / 42 (9.52%) 12 | 6 / 42 (14.29%) 10 | 5 / 32 (15.63%) 6 |
| Lymphopenia subjects affected / exposed occurrences (all) | 4 / 42 (9.52%) 9 | 3 / 42 (7.14%) 7 | 1 / 32 (3.13%) 1 |
| Neutropenia subjects affected / exposed occurrences (all) | 2 / 42 (4.76%) 3 | 2 / 42 (4.76%) 3 | 1 / 32 (3.13%) 1 |
| Ear and labyrinth disorders | | | |
| Ear discomfort subjects affected / exposed occurrences (all) | 0 / 42 (0.00%) 0 | 0 / 42 (0.00%) 0 | 0 / 32 (0.00%) 0 |
| Eye disorders | | | |
| Conjunctival haemorrhage subjects affected / exposed occurrences (all) | 0 / 42 (0.00%) 0 | 1 / 42 (2.38%) 1 | 2 / 32 (6.25%) 4 |
| Blepharitis subjects affected / exposed occurrences (all) | 0 / 42 (0.00%) 0 | 0 / 42 (0.00%) 0 | 0 / 32 (0.00%) 0 |
| Gastrointestinal disorders | | | |

| | | | |
|--|----------------------|---------------------|----------------------|
| Abdominal pain upper subjects affected / exposed occurrences (all) | 1 / 42 (2.38%) 1 | 1 / 42 (2.38%) 1 | 2 / 32 (6.25%) 2 |
| Constipation subjects affected / exposed occurrences (all) | 7 / 42 (16.67%) 8 | 2 / 42 (4.76%) 2 | 2 / 32 (6.25%) 4 |
| Dental caries subjects affected / exposed occurrences (all) | 2 / 42 (4.76%) 2 | 2 / 42 (4.76%) 2 | 5 / 32 (15.63%) 5 |
| Diarrhoea subjects affected / exposed occurrences (all) | 3 / 42 (7.14%) 3 | 1 / 42 (2.38%) 3 | 5 / 32 (15.63%) 5 |
| Gastritis subjects affected / exposed occurrences (all) | 0 / 42 (0.00%) 0 | 2 / 42 (4.76%) 2 | 2 / 32 (6.25%) 3 |
| Nausea subjects affected / exposed occurrences (all) | 3 / 42 (7.14%) 3 | 3 / 42 (7.14%) 3 | 0 / 32 (0.00%) 0 |
| Toothache subjects affected / exposed occurrences (all) | 1 / 42 (2.38%) 1 | 0 / 42 (0.00%) 0 | 4 / 32 (12.50%) 5 |
| Abdominal pain subjects affected / exposed occurrences (all) | 0 / 42 (0.00%) 0 | 2 / 42 (4.76%) 2 | 2 / 32 (6.25%) 2 |
| Haemorrhoids subjects affected / exposed occurrences (all) | 0 / 42 (0.00%) 0 | 2 / 42 (4.76%) 2 | 0 / 32 (0.00%) 0 |
| Vomiting subjects affected / exposed occurrences (all) | 2 / 42 (4.76%) 2 | 2 / 42 (4.76%) 2 | 0 / 32 (0.00%) 0 |
| Skin and subcutaneous tissue disorders | | | |
| Urticaria subjects affected / exposed occurrences (all) | 0 / 42 (0.00%) 0 | 3 / 42 (7.14%) 3 | 2 / 32 (6.25%) 3 |
| Eczema | | | |

| | | | |
|---|----------------------|---------------------|----------------------|
| subjects affected / exposed occurrences (all) | 1 / 42 (2.38%) 1 | 2 / 42 (4.76%) 2 | 2 / 32 (6.25%) 2 |
| Rash subjects affected / exposed occurrences (all) | 2 / 42 (4.76%) 2 | 0 / 42 (0.00%) 0 | 1 / 32 (3.13%) 1 |
| Pruritus subjects affected / exposed occurrences (all) | 1 / 42 (2.38%) 1 | 1 / 42 (2.38%) 1 | 1 / 32 (3.13%) 1 |
| Renal and urinary disorders Leukocyturia subjects affected / exposed occurrences (all) | 3 / 42 (7.14%) 3 | 2 / 42 (4.76%) 2 | 1 / 32 (3.13%) 1 |
| Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all) | 0 / 42 (0.00%) 0 | 4 / 42 (9.52%) 4 | 2 / 32 (6.25%) 2 |
| Back pain subjects affected / exposed occurrences (all) | 5 / 42 (11.90%) 9 | 4 / 42 (9.52%) 4 | 1 / 32 (3.13%) 1 |
| Myalgia subjects affected / exposed occurrences (all) | 1 / 42 (2.38%) 1 | 1 / 42 (2.38%) 5 | 3 / 32 (9.38%) 3 |
| Pain in extremity subjects affected / exposed occurrences (all) | 3 / 42 (7.14%) 3 | 1 / 42 (2.38%) 1 | 0 / 32 (0.00%) 0 |
| Muscle spasms subjects affected / exposed occurrences (all) | 0 / 42 (0.00%) 0 | 0 / 42 (0.00%) 0 | 0 / 32 (0.00%) 0 |
| Infections and infestations Cystitis subjects affected / exposed occurrences (all) | 4 / 42 (9.52%) 6 | 4 / 42 (9.52%) 5 | 3 / 32 (9.38%) 3 |
| Influenza subjects affected / exposed occurrences (all) | 4 / 42 (9.52%) 5 | 0 / 42 (0.00%) 0 | 4 / 32 (12.50%) 5 |
| Nasopharyngitis | | | |

| | | | |
|-----------------------------------|-----------------|------------------|------------------|
| subjects affected / exposed | 7 / 42 (16.67%) | 10 / 42 (23.81%) | 11 / 32 (34.38%) |
| occurrences (all) | 13 | 22 | 49 |
| Oral herpes | | | |
| subjects affected / exposed | 3 / 42 (7.14%) | 2 / 42 (4.76%) | 4 / 32 (12.50%) |
| occurrences (all) | 19 | 6 | 42 |
| Pharyngitis | | | |
| subjects affected / exposed | 3 / 42 (7.14%) | 4 / 42 (9.52%) | 0 / 32 (0.00%) |
| occurrences (all) | 10 | 6 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 3 / 42 (7.14%) | 0 / 32 (0.00%) |
| occurrences (all) | 0 | 5 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 3 / 42 (7.14%) | 3 / 32 (9.38%) |
| occurrences (all) | 0 | 4 | 3 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 6 / 42 (14.29%) | 10 / 42 (23.81%) | 8 / 32 (25.00%) |
| occurrences (all) | 12 | 26 | 10 |
| Urinary tract infection | | | |
| subjects affected / exposed | 7 / 42 (16.67%) | 6 / 42 (14.29%) | 6 / 32 (18.75%) |
| occurrences (all) | 7 | 8 | 16 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 1 / 42 (2.38%) | 1 / 32 (3.13%) |
| occurrences (all) | 0 | 1 | 1 |
| Hordeolum | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 2 / 32 (6.25%) |
| occurrences (all) | 0 | 0 | 2 |
| Otitis externa | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 2 / 32 (6.25%) |
| occurrences (all) | 0 | 0 | 2 |
| Periodontitis | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 1 / 42 (2.38%) | 3 / 32 (9.38%) |
| occurrences (all) | 0 | 1 | 6 |
| Bronchitis | | | |
| subjects affected / exposed | 1 / 42 (2.38%) | 2 / 42 (4.76%) | 1 / 32 (3.13%) |
| occurrences (all) | 1 | 5 | 1 |
| Ear infection | | | |

| | | | |
|------------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 42 (0.00%) | 1 / 42 (2.38%) | 1 / 32 (3.13%) |
| occurrences (all) | 0 | 1 | 1 |
| Gastroenteritis | | | |
| subjects affected / exposed | 1 / 42 (2.38%) | 1 / 42 (2.38%) | 2 / 32 (6.25%) |
| occurrences (all) | 1 | 2 | 8 |
| Laryngitis | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 1 / 32 (3.13%) |
| occurrences (all) | 0 | 0 | 1 |
| Localised infection | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 0 / 42 (0.00%) | 0 / 32 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tonsillitis | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 1 / 42 (2.38%) | 1 / 32 (3.13%) |
| occurrences (all) | 0 | 1 | 1 |
| Varicella zoster virus infection | | | |
| subjects affected / exposed | 0 / 42 (0.00%) | 1 / 42 (2.38%) | 2 / 32 (6.25%) |
| occurrences (all) | 0 | 1 | 2 |
| Metabolism and nutrition disorders | | | |
| Dyslipidaemia | | | |
| subjects affected / exposed | 1 / 42 (2.38%) | 1 / 42 (2.38%) | 2 / 32 (6.25%) |
| occurrences (all) | 1 | 1 | 2 |
| Hypercholesterolaemia | | | |
| subjects affected / exposed | 5 / 42 (11.90%) | 4 / 42 (9.52%) | 2 / 32 (6.25%) |
| occurrences (all) | 5 | 10 | 2 |

| Non-serious adverse events | Satralizumab + Baseline Treatment Open Label period | Satralizumab Open- Label Period | |
|--|---|------------------------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 30 / 39 (76.92%) | 1 / 1 (100.00%) | |
| Vascular disorders | | | |
| Flushing | | | |
| subjects affected / exposed | 2 / 39 (5.13%) | 0 / 1 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Hypertension | | | |
| subjects affected / exposed | 2 / 39 (5.13%) | 0 / 1 (0.00%) | |
| occurrences (all) | 7 | 0 | |
| Hypotension | | | |

| | | | |
|---|---------------------|----------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 39 (0.00%) 0 | 1 / 1 (100.00%) 1 | |
| General disorders and administration site conditions | | | |
| Fatigue | | | |
| subjects affected / exposed occurrences (all) | 0 / 39 (0.00%) 0 | 0 / 1 (0.00%) 0 | |
| Pyrexia | | | |
| subjects affected / exposed occurrences (all) | 0 / 39 (0.00%) 0 | 0 / 1 (0.00%) 0 | |
| Non-cardiac chest pain | | | |
| subjects affected / exposed occurrences (all) | 1 / 39 (2.56%) 1 | 0 / 1 (0.00%) 0 | |
| Immune system disorders | | | |
| Hypocomplementaemia | | | |
| subjects affected / exposed occurrences (all) | 2 / 39 (5.13%) 5 | 0 / 1 (0.00%) 0 | |
| Reproductive system and breast disorders | | | |
| Dysmenorrhoea | | | |
| subjects affected / exposed occurrences (all) | 0 / 39 (0.00%) 0 | 1 / 1 (100.00%) 1 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed occurrences (all) | 3 / 39 (7.69%) 3 | 0 / 1 (0.00%) 0 | |
| Oropharyngeal pain | | | |
| subjects affected / exposed occurrences (all) | 2 / 39 (5.13%) 2 | 1 / 1 (100.00%) 1 | |
| Rhinorrhoea | | | |
| subjects affected / exposed occurrences (all) | 2 / 39 (5.13%) 3 | 0 / 1 (0.00%) 0 | |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed occurrences (all) | 2 / 39 (5.13%) 2 | 0 / 1 (0.00%) 0 | |
| Insomnia | | | |

| | | | |
|--|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Depression | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Investigations | | | |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 5 / 39 (12.82%) | 0 / 1 (0.00%) | |
| occurrences (all) | 5 | 0 | |
| Blood fibrinogen decreased | | | |
| subjects affected / exposed | 2 / 39 (5.13%) | 0 / 1 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Blood fibrinogen increased | | | |
| subjects affected / exposed | 2 / 39 (5.13%) | 0 / 1 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Blood pressure increased | | | |
| subjects affected / exposed | 2 / 39 (5.13%) | 0 / 1 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 1 / 1 (100.00%) | |
| occurrences (all) | 2 | 1 | |
| Prothrombin time prolonged | | | |
| subjects affected / exposed | 2 / 39 (5.13%) | 0 / 1 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| White blood cell count decreased | | | |

| | | | |
|--|----------------|-----------------|--|
| subjects affected / exposed | 1 / 39 (2.56%) | 1 / 1 (100.00%) | |
| occurrences (all) | 2 | 1 | |
| Blood cholesterol increased | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Haemoglobin decreased | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 1 / 1 (100.00%) | |
| occurrences (all) | 2 | 1 | |
| Lymphocyte percentage decreased | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 1 / 1 (100.00%) | |
| occurrences (all) | 0 | 1 | |
| Lymphocyte percentage increased | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 1 / 1 (100.00%) | |
| occurrences (all) | 1 | 1 | |
| Monocyte count increased | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 1 / 1 (100.00%) | |
| occurrences (all) | 0 | 1 | |
| Neutrophil count increased | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 1 / 1 (100.00%) | |
| occurrences (all) | 2 | 1 | |
| Neutrophil percentage increased | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 1 / 1 (100.00%) | |
| occurrences (all) | 1 | 1 | |
| Platelet count increased | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 1 / 1 (100.00%) | |
| occurrences (all) | 0 | 1 | |
| White blood cell count increased | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 1 / 1 (100.00%) | |
| occurrences (all) | 1 | 1 | |
| Injury, poisoning and procedural complications | | | |
| Fall | | | |
| subjects affected / exposed | 2 / 39 (5.13%) | 0 / 1 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Ligament sprain | | | |

| | | | |
|--------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Thermal burn | | | |
| subjects affected / exposed | 2 / 39 (5.13%) | 0 / 1 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Rib fracture | | | |
| subjects affected / exposed | 2 / 39 (5.13%) | 0 / 1 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Headache | | | |
| subjects affected / exposed | 6 / 39 (15.38%) | 1 / 1 (100.00%) | |
| occurrences (all) | 10 | 1 | |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 5 / 39 (12.82%) | 0 / 1 (0.00%) | |
| occurrences (all) | 7 | 0 | |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Leukopenia | | | |
| subjects affected / exposed | 4 / 39 (10.26%) | 0 / 1 (0.00%) | |
| occurrences (all) | 10 | 0 | |
| Lymphopenia | | | |
| subjects affected / exposed | 4 / 39 (10.26%) | 0 / 1 (0.00%) | |
| occurrences (all) | 14 | 0 | |
| Neutropenia | | | |

| | | | |
|--|---|--|--|
| subjects affected / exposed occurrences (all) | 2 / 39 (5.13%) 5 | 0 / 1 (0.00%) 0 | |
| Ear and labyrinth disorders Ear discomfort subjects affected / exposed occurrences (all) | 2 / 39 (5.13%) 2 | 0 / 1 (0.00%) 0 | |
| Eye disorders Conjunctival haemorrhage subjects affected / exposed occurrences (all) Blepharitis subjects affected / exposed occurrences (all) | 3 / 39 (7.69%) 3 2 / 39 (5.13%) 2 | 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 | |
| Gastrointestinal disorders Abdominal pain upper subjects affected / exposed occurrences (all) Constipation subjects affected / exposed occurrences (all) Dental caries subjects affected / exposed occurrences (all) Diarrhoea subjects affected / exposed occurrences (all) Gastritis subjects affected / exposed occurrences (all) Nausea subjects affected / exposed occurrences (all) Toothache subjects affected / exposed occurrences (all) Abdominal pain | 1 / 39 (2.56%) 1 2 / 39 (5.13%) 3 2 / 39 (5.13%) 2 3 / 39 (7.69%) 5 2 / 39 (5.13%) 2 0 / 39 (0.00%) 0 1 / 39 (2.56%) 1 | 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 1 / 1 (100.00%) 2 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 | |

| | | | |
|---|---------------------|----------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 39 (0.00%) 0 | 1 / 1 (100.00%) 1 | |
| Haemorrhoids subjects affected / exposed occurrences (all) | 1 / 39 (2.56%) 1 | 1 / 1 (100.00%) 1 | |
| Vomiting subjects affected / exposed occurrences (all) | 1 / 39 (2.56%) 1 | 0 / 1 (0.00%) 0 | |
| Skin and subcutaneous tissue disorders Urticaria subjects affected / exposed occurrences (all) | 1 / 39 (2.56%) 1 | 0 / 1 (0.00%) 0 | |
| Eczema subjects affected / exposed occurrences (all) | 3 / 39 (7.69%) 3 | 0 / 1 (0.00%) 0 | |
| Rash subjects affected / exposed occurrences (all) | 2 / 39 (5.13%) 4 | 1 / 1 (100.00%) 1 | |
| Pruritus subjects affected / exposed occurrences (all) | 0 / 39 (0.00%) 0 | 1 / 1 (100.00%) 1 | |
| Renal and urinary disorders Leukocyturia subjects affected / exposed occurrences (all) | 0 / 39 (0.00%) 0 | 0 / 1 (0.00%) 0 | |
| Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all) | 3 / 39 (7.69%) 3 | 0 / 1 (0.00%) 0 | |
| Back pain subjects affected / exposed occurrences (all) | 1 / 39 (2.56%) 1 | 0 / 1 (0.00%) 0 | |
| Myalgia subjects affected / exposed occurrences (all) | 2 / 39 (5.13%) 2 | 0 / 1 (0.00%) 0 | |
| Pain in extremity | | | |

| | | | |
|-----------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 2 / 39 (5.13%) | 0 / 1 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Muscle spasms | | | |
| subjects affected / exposed | 2 / 39 (5.13%) | 0 / 1 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Infections and infestations | | | |
| Cystitis | | | |
| subjects affected / exposed | 2 / 39 (5.13%) | 0 / 1 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| Influenza | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 7 / 39 (17.95%) | 0 / 1 (0.00%) | |
| occurrences (all) | 15 | 0 | |
| Oral herpes | | | |
| subjects affected / exposed | 3 / 39 (7.69%) | 0 / 1 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| Pharyngitis | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Rhinitis | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 1 / 1 (100.00%) | |
| occurrences (all) | 1 | 1 | |
| Sinusitis | | | |
| subjects affected / exposed | 2 / 39 (5.13%) | 0 / 1 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 8 / 39 (20.51%) | 0 / 1 (0.00%) | |
| occurrences (all) | 36 | 0 | |
| Urinary tract infection | | | |
| subjects affected / exposed | 5 / 39 (12.82%) | 0 / 1 (0.00%) | |
| occurrences (all) | 23 | 0 | |
| Conjunctivitis | | | |
| subjects affected / exposed | 2 / 39 (5.13%) | 0 / 1 (0.00%) | |
| occurrences (all) | 2 | 0 | |

| | | | |
|------------------------------------|----------------|-----------------|--|
| Hordeolum | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Otitis externa | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Periodontitis | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 0 / 1 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Bronchitis | | | |
| subjects affected / exposed | 2 / 39 (5.13%) | 0 / 1 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Ear infection | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 1 / 1 (100.00%) | |
| occurrences (all) | 0 | 2 | |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Laryngitis | | | |
| subjects affected / exposed | 2 / 39 (5.13%) | 0 / 1 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| Localised infection | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 1 / 1 (100.00%) | |
| occurrences (all) | 0 | 1 | |
| Tonsillitis | | | |
| subjects affected / exposed | 1 / 39 (2.56%) | 1 / 1 (100.00%) | |
| occurrences (all) | 1 | 1 | |
| Varicella zoster virus infection | | | |
| subjects affected / exposed | 0 / 39 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Metabolism and nutrition disorders | | | |
| Dyslipidaemia | | | |
| subjects affected / exposed | 2 / 39 (5.13%) | 0 / 1 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Hypercholesterolaemia | | | |

| | | | |
|-----------------------------|----------------|---------------|--|
| subjects affected / exposed | 2 / 39 (5.13%) | 0 / 1 (0.00%) | |
| occurrences (all) | 4 | 0 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|---|
| 29 November 2013 | Definition of NMOSD was changed. The population was limited to optic neuritis or transverse myelitis with seropositivity in anti-AQP4 antibody. Adolescent subjects aged 12-17 years were allowed to enter the study. Considering the impact of previous treatment on safety and efficacy, the treatment prohibited duration was modified. Methods and duration of contraception were added to exclusion criteria. Because patients with NMO/NMOSD tend to show lower white blood cell value due to baseline treatment with immunosuppressant drugs, the white blood cell exclusion criterion was modified. The protocol v2 was released prior to any patients being enrolled in the study. |
| 27 February 2014 | Suicidality assessment (C-SSRS) was added as a safety objective per Food and Drug Administration (FDA) request. Based on epidemiologic data, the percentage of patients with negative anti-AQP4 serostatus at screening was capped at 30% in order to reflect the real world population. Further clarifications on the process of screening for potential clinical relapses were added. The roles and responsibilities of the treating and assessing investigator were introduced and the blinding of study and site personnel to certain laboratory parameters were clarified. |
| 18 December 2014 | The criteria for protocol-defined relapse (PDR) were aligned with another pivotal Phase III study in patients with NMO/NMOSD (study BN40900 / SA309JG/ EudraCT ID 2015-005431-41), which was modified based on FDA's comment. According to the Paediatric Committee's (PDCO's) request at least 8 adolescents were to be enrolled. Combination baseline treatment for adolescents was allowed given the low prevalence of pediatric patients and their treatment situation. Additional follow up assessments for adolescents were added. A blood sample collected before screening was accepted for anti-AQP4 antibody screening assessment in case the blood sample at screening was negative for anti-AQP4 antibody, considering the possibility that anti-AQP4 antibody status may change from positive to negative due to treatment for relapse. Permitted relapse treatments and prohibited treatments were modified considering clinical practice. Time limit of relapse evaluation to be recognized as PDR was aligned to another pivotal Phase III study in participants with NMO/NMOSD (study BN40900/SA-309JG// EudraCT ID 2015-005431-41) to avoid incomplete or biased reporting, and relapse assessment procedures were clarified. To avoid missing potential relapses, additional phone calls between visits and instructions to remind participants of possible relapse symptoms were added. The conditions when a participant could move from the double blind (DB) period to the open-label extension (OLE) period were clarified. |
| 03 June 2015 | Considering the clinical situation where no drugs have been approved for treatment of NMO and NMOSD, the open-label extension period was extended from an ethical point of view. This change was also in alignment with the agreed pediatric investigation plan (PIP). Inclusion of adolescents with negative anti-AQP4 serostatus at screening was allowed. |
| 19 October 2015 | Clarification that the population which was capped by anti-AQP4 antibody status at screening was limited only to adults. |
| 14 December 2016 | Addition that adolescents may be enrolled into the OLE period after the total number of PDRs confirmed by the clinical endpoint committee (CEC) reached 26. The minimum number of adolescents (12 to 17 years old) with positive anti-AQP4 serostatus at screening was changed from 6 to 4. The use of satralizumab prefilled syringe (PFS) with needle safety device (NSD) were implemented to be used in the OLE period after the total number of CEC confirmed PDRs reached 26. |

| | |
|---------------|--|
| 17 April 2017 | The description on the timing of satralizumab PFS with NSD implementation was modified so that satralizumab PFS with NSD could be administered for participants who had already entered into open-label extension period after availability at each study site. The reporting procedure when the medical device (satralizumab PFS with NSD) resulted in an adverse event (AE) to an individual other than the study participant was clarified. |
|---------------|--|

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported